0000891618-95-000530.txt : 19950914 0000891618-95-000530.hdr.sgml : 19950914 ACCESSION NUMBER: 0000891618-95-000530 CONFORMED SUBMISSION TYPE: S-3 PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 19950908 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: SILICON VALLEY GROUP INC CENTRAL INDEX KEY: 0000712752 STANDARD INDUSTRIAL CLASSIFICATION: SPECIAL INDUSTRY MACHINERY, NEC [3559] IRS NUMBER: 942264681 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: S-3 SEC ACT: 1933 Act SEC FILE NUMBER: 033-62455 FILM NUMBER: 95572234 BUSINESS ADDRESS: STREET 1: 2240 RINGWOOD AVE CITY: SAN JOSE STATE: CA ZIP: 95131 BUSINESS PHONE: 4084340500 MAIL ADDRESS: STREET 1: 2240 RINGWOOD AVENUE CITY: SAN JOSE STATE: CA ZIP: 95131 S-3 1 FORM S-3 1 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 8, 1995 REGISTRATION NO. -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------------------ FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ------------------------ SILICON VALLEY GROUP, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE 94-2264681 (STATE OR OTHER JURISDICTION OF INCORPORATION (I.R.S. EMPLOYER IDENTIFICATION NUMBER) OR ORGANIZATION)
2240 RINGWOOD AVENUE SAN JOSE, CALIFORNIA 95131 (408) 434-0500 (ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES) ------------------------ RUSSELL G. WEINSTOCK VICE PRESIDENT, FINANCE AND CHIEF FINANCIAL OFFICER 2240 RINGWOOD AVENUE SAN JOSE, CALIFORNIA 95131 (408) 434-0500 (NAME, ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF AGENT FOR SERVICE) ------------------------ COPIES TO: LARRY W. SONSINI, ESQ. WILLIAM D. SHERMAN, ESQ. ROBERT T. CLARKSON, ESQ. C. JEFFREY CHAR, ESQ. AARON J. ALTER, ESQ. MORRISON & FOERSTER ADELE C. FREEDMAN, ESQ. 755 PAGE MILL ROAD WILSON, SONSINI, GOODRICH & ROSATI PALO ALTO, CALIFORNIA 94304 PROFESSIONAL CORPORATION (415) 813-5600 650 PAGE MILL ROAD PALO ALTO, CALIFORNIA 94304 (415) 493-9300
------------------------ APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: As soon as practicable after the effective date of this Registration Statement. If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. / / If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the "Securities Act"), other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. / / If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. / / If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. / / If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. / / ------------------------ CALCULATION OF REGISTRATION FEE -------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- PROPOSED PROPOSED MAXIMUM MAXIMUM TITLE OF SECURITIES AMOUNT TO BE OFFERING PRICE AGGREGATE AMOUNT OF TO BE REGISTERED REGISTERED(1) PER SHARE(2) OFFERING PRICE(2) REGISTRATION FEE ------------------------------------------------------------------------------------------------- Common Stock, $0.01 par value.................. 4,025,000 shares $179,364,063 $44.5625 $61,850 ------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------
(1) Includes 525,000 shares which the Underwriters have the option to purchase to cover over-allotments, if any. (2) Estimated solely for the purpose of calculating the registration fee based on the average of the high and low prices of the Registrant's Common Stock on the Nasdaq National Market on September 6, 1995. ------------------------ THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A), MAY DETERMINE. -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- 2 EXPLANATORY NOTE This Registration Statement contains two forms of prospectuses: one to be used in connection with an offering in the United States and the other to be used in connection with a concurrent international offering (the "International Prospectus"). The two prospectuses are identical except for the outside and inside front cover pages. The alternate pages for the International Prospectus are included herein and labeled "Alternate Page." 3 INFORMATION CONTAINED HEREIN IS SUBJECT TO COMPLETION OR AMENDMENT. A REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE REGISTRATION STATEMENT BECOMES EFFECTIVE. THIS PROSPECTUS SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH STATE. PROSPECTUS (Subject to Completion) Issued September , 1995 3,500,000 Shares (LOGO) COMMON STOCK ------------------------ OF THE 3,500,000 SHARES OF COMMON STOCK BEING OFFERED, 2,800,000 SHARES ARE BEING OFFERED INITIALLY IN THE UNITED STATES AND CANADA BY THE U.S. UNDERWRITERS AND 700,000 SHARES ARE BEING OFFERED INITIALLY OUTSIDE OF THE UNITED STATES AND CANADA BY THE INTERNATIONAL UNDERWRITERS. SEE "UNDERWRITERS." ALL OF THE SHARES OF COMMON STOCK OFFERED HEREBY ARE BEING SOLD BY THE COMPANY. THE COMPANY'S COMMON STOCK IS TRADED IN THE OVER-THE-COUNTER MARKET UNDER THE NASDAQ NATIONAL MARKET SYMBOL "SVGI." THE LAST SALE PRICE FOR THE COMMON STOCK ON SEPTEMBER 7, 1995, AS REPORTED ON THE NASDAQ NATIONAL MARKET, WAS $44 1/8 PER SHARE. SEE "PRICE RANGE OF COMMON STOCK." ------------------------ THIS OFFERING INVOLVES A HIGH DEGREE OF RISK. SEE "RISK FACTORS" COMMENCING ON PAGE 6. ------------------------ THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. ------------------------ PRICE $ A SHARE ------------------------
UNDERWRITING PRICE TO DISCOUNTS AND PROCEEDS TO PUBLIC COMMISSIONS(1) COMPANY(2) ---------------- ---------------- ---------------- Per Share..................................... $ $ $ Total(3)...................................... $ $ $
------------ (1) The Company has agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended. See "Underwriters." (2) Before deducting expenses payable by the Company estimated at $350,000. (3) The Company has granted to the U.S. Underwriters an option, exercisable within 30 days of the date hereof, to purchase up to 525,000 additional Shares at the price to public less underwriting discounts and commissions for the purpose of covering over-allotments, if any. If the U.S. Underwriters exercise such option in full, the total price to public, underwriting discounts and commissions and proceeds to Company will be $ , $ , and $ , respectively. See "Underwriters." ------------------------ The Shares are offered subject to prior sale, when, as and if accepted by the Underwriters named herein and subject to approval of certain legal matters by Morrison & Foerster, counsel for the Underwriters. It is expected that delivery of the Shares will be made on or about , 1995 at the offices of Morgan Stanley & Co. Incorporated, New York, N.Y., against payment therefor in New York funds. ------------------------ MORGAN STANLEY & CO. Incorporated PRUDENTIAL SECURITIES INCORPORATED COWEN & COMPANY , 1995 4 NO PERSON IS AUTHORIZED IN CONNECTION WITH ANY OFFERING MADE HEREBY TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATION NOT CONTAINED OR INCORPORATED BY REFERENCE IN THIS PROSPECTUS, AND ANY INFORMATION OR REPRESENTATION NOT CONTAINED OR INCORPORATED HEREIN MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY OR ANY UNDERWRITER. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY BY ANY PERSON IN ANY JURISDICTION IN WHICH IT IS UNLAWFUL FOR SUCH PERSON TO MAKE SUCH AN OFFERING OR SOLICITATION. NEITHER THE DELIVERY OF THIS PROSPECTUS AT ANY TIME NOR ANY SALE MADE HEREUNDER SHALL UNDER ANY CIRCUMSTANCE IMPLY THAT THE INFORMATION HEREIN IS CORRECT AS OF ANY DATE SUBSEQUENT TO THE DATE HEREOF. ------------------------ TABLE OF CONTENTS
PAGE ---- Incorporation of Certain Documents by Reference............................................ 2 Prospectus Summary......................................................................... 3 The Company................................................................................ 4 Risk Factors............................................................................... 6 Use of Proceeds............................................................................ 11 Price Range of Common Stock................................................................ 12 Dividend Policy............................................................................ 12 Capitalization............................................................................. 13 Selected Consolidated Financial Data....................................................... 14 Business................................................................................... 16 Underwriters............................................................................... 23 Legal Matters.............................................................................. 25 Experts.................................................................................... 25 Available Information...................................................................... 26
------------------------ INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE The following documents heretofore filed by the Company with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act") are incorporated herein by reference: (1) the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 1994; (2) the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 1994; (3) the Company's Current Report on Form 8-K filed on March 2, 1995; (4) the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 1995; (5) the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 1995; and (6) the Company's Registration Statement on Form 8-A filed with the Commission on November 23, 1983. All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this Prospectus and prior to the termination of the offering of the Common Stock hereunder shall be deemed to be incorporated by reference herein and to be a part hereof from the date of the filing of such reports and documents. The Company will provide a copy of any or all of such documents (exclusive of exhibits unless such exhibits are specifically incorporated by reference herein), without charge, to each person to whom this Prospectus is delivered, upon written or oral request to the Chief Financial Officer at the corporate headquarters of the Company, 2240 Ringwood Avenue, San Jose, California 95131 (telephone 408-434-0500). Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Prospectus to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Prospectus. ------------------------ IN CONNECTION WITH THIS OFFERING, THE UNDERWRITERS MAY OVER-ALLOT OR EFFECT TRANSACTIONS WHICH STABILIZE OR MAINTAIN THE MARKET PRICE OF THE COMMON STOCK OFFERED HEREBY AT A LEVEL ABOVE THAT WHICH MIGHT OTHERWISE PREVAIL IN THE OPEN MARKET. SUCH TRANSACTIONS MAY BE EFFECTED ON THE NASDAQ NATIONAL MARKET, IN THE OVER-THE-COUNTER MARKET OR OTHERWISE. SUCH STABILIZING, IF COMMENCED, MAY BE DISCONTINUED AT ANY TIME. THE U.S. SHARES MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, OUTSIDE THE UNITED STATES OR CANADA OR TO ANY PERSON WHO IS NOT A UNITED STATES OR CANADIAN PERSON, AS PART OF THE DISTRIBUTION OF THE U.S. SHARES. FOR A DESCRIPTION OF THIS AND OTHER RESTRICTIONS ON THE OFFERING AND SALE OF THESE SHARES, SEE "UNDERWRITERS." IN CONNECTION WITH THIS OFFERING, CERTAIN UNDERWRITERS AND SELLING GROUP MEMBERS (IF ANY) OR THEIR RESPECTIVE AFFILIATES MAY ENGAGE IN PASSIVE MARKET MAKING TRANSACTIONS IN THE COMMON STOCK ON THE NASDAQ NATIONAL MARKET IN ACCORDANCE WITH RULE 10B-6A UNDER THE SECURITIES EXCHANGE ACT OF 1934. SEE "UNDERWRITERS." 2 5 PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements appearing elsewhere or incorporated by reference in this Prospectus. THE COMPANY Silicon Valley Group, Inc. designs, manufactures, markets and services semiconductor fabrication equipment for the worldwide semiconductor industry. The Company has three principal product groups which focus primarily on photolithography, photoresist processing, and deposition for oxidation/diffusion and low pressure chemical vapor deposition. The Company's products incorporate proprietary technologies and unique processes, and focus on providing process and product technologies and productivity enhancements to its customers. SVG believes that its Micrascan step and scan photolithography exposure system, which utilizes a deep ultraviolet light source allowing line widths of 0.35 micron and below, is the most technologically advanced machine currently being shipped in quantity to global semiconductor manufacturers. The Company supports its reliable, cost-effective products through a network of worldwide service and technical support organizations. The Company works closely with its existing and potential customers, including leading semiconductor manufacturers such as Analog Devices, Cypress Semiconductor, Hewlett-Packard, Intel, IBM, LG Semicon, Loral, Motorola, Philips Semiconductor, SGS-Thomson, Samsung, Siemens, Symbios Logic and Texas Instruments. As evidence of the Company's commitment to its customers, in February 1995 the Company entered into a business relationship with Intel, Motorola and Texas Instruments pursuant to which such companies made an equity investment in the Company. Additionally, SEMATECH and IBM have made an equity investment in the Company and its subsidiary, SVGL, respectively. THE OFFERING U.S. offering(1).......................... 2,800,000 Shares International offering.................... 700,000 Shares Total(1)......................... 3,500,000 Shares Common Stock to be outstanding after the offering.................................. 28,720,921 Shares(1)(2) Use of proceeds........................... For certain capital expenditures and facility expansion related to increasing production primarily at SVGL and for working capital, research and development and other general corporate purposes. See "Use of Proceeds." The Nasdaq National Market symbol......... SVGI SUMMARY CONSOLIDATED FINANCIAL DATA (IN THOUSANDS, EXCEPT PER SHARE DATA)
NINE MONTHS ENDED FISCAL YEAR ENDED SEPTEMBER 30, JUNE 30, -------------------------------------------------------- -------------------- 1990(3) 1991 1992 1993 1994 1994 1995 -------- -------- -------- -------- -------- -------- -------- CONSOLIDATED INCOME STATEMENT DATA: Net sales................................. $184,289 $234,798 $192,457 $240,633 $319,922 $237,942 $323,073 Gross profit.............................. 73,848 85,461 77,161 93,426 124,411 92,216 126,896 Operating income.......................... 8,269 4,796 1,608 7,384 26,451 19,238 34,184 Net income (loss)......................... 4,449 1,641 (292) 4,485 16,764 11,780 24,861 Net income (loss) per common share........ $ 0.42 $ 0.12 $ (0.03) $ 0.22 $ 0.84 $ 0.60 $ 1.04 Shares used in per share computation...... 10,708 13,166 14,754 15,277 18,538 18,212 23,973
JUNE 30, 1995 --------------------------- ACTUAL AS ADJUSTED(4) -------- -------------- CONSOLIDATED BALANCE SHEET DATA: Cash and equivalents.................................................................. $194,472 $342,189 Working capital....................................................................... 312,068 459,785 Total assets.......................................................................... 471,702 619,419 Short-term debt and current portion of long-term debt................................. 877 877 Long-term debt and capital leases..................................................... 874 874 Stockholders' equity.................................................................. 330,695 478,412
--------------- (1) Assumes the Underwriters' over-allotment option to purchase 525,000 shares from the Company is not exercised. See "Underwriters." (2) Based on shares outstanding on August 31, 1995. Excludes (i) 1,534,750 shares issuable upon exercise of outstanding stock options at a weighted average exercise price of $16.82 per share and (ii) 1,750,000 shares issuable upon exercise of a warrant with an exercise price of $13.625 per share. (3) Includes the results of operations of one of the Company's subsidiaries, SVG Lithography Systems, Inc. ("SVGL") from May 1, 1990. (4) Gives effect to the sale of the 3,500,000 shares offered hereby by the Company at an assumed per share offering price of $44.125 (the last reported sale price of the Common Stock on September 7, 1995) and the anticipated use of the net proceeds therefrom. 3 6 THE COMPANY Silicon Valley Group, Inc. ("SVG" or the "Company") designs, manufactures, markets and services semiconductor fabrication equipment for the worldwide semiconductor industry. The Company has three principal product groups which focus primarily on photolithography, photoresist processing, deposition for oxidation/diffusion and low pressure chemical vapor deposition ("LPCVD"). The Company supports its reliable, cost-effective products through a network of worldwide service and technical support organizations. The Company works closely with its existing and potential customers, including leading semiconductor manufacturers such as Analog Devices, Cypress Semiconductor, Hewlett-Packard, Intel, IBM, LG Semicon, Loral, Motorola, Philips Semiconductor, SGS-Thomson, Samsung, Siemens, Symbios Logic and Texas Instruments. The Company's products incorporate proprietary technologies and unique processes and focus on providing process and product technologies and productivity enhancements to customers. The Company manufactures and markets its photolithography exposure products through its majority owned subsidiary, SVG Lithography Systems, Inc. ("SVGL"), its photoresist processing products through its Track Systems Division ("Track") and its oxidation/diffusion and LPCVD products through its Thermco Systems Division ("Thermco"). SVG LITHOGRAPHY SYSTEMS, INC. designs, manufactures, markets and services advanced photolithography exposure systems. SVGL has two broad families, Micrascan step and scan systems and the more mature Micralign scanning projection aligners. The Company believes that its Micrascan photolithography exposure system provides the greater resolution required for the next generation of complex, fine geometry integrated circuits through its use of a deep ultraviolet ("Deep UV") light source and overcomes the throughput and yield limitations of steppers by combining the elements of both steppers and scanners into the Micrascan's "step and scan" technology. The Company also believes that its Micrascan step and scan photolithography exposure system is the most technologically advanced machine currently being shipped in quantity to global semiconductor manufacturers. In addition, it believes that as larger and more complex logic and memory devices move from development to production, semiconductor manufacturers will have a greater incentive to purchase SVGL's step and scan systems rather than steppers to achieve higher yields, faster throughput and more precise line-width control. TRACK SYSTEMS DIVISION designs, manufacturers, markets and services equipment which performs all the steps necessary to process semiconductor wafers prior to photolithography exposure, including cleaning, adhesion promotion and photoresist coating, and which performs all the steps required to treat wafers after photolithography exposure prior to etching, including developing and baking. As photoresist processing technology has evolved, the Company has developed increasingly advanced products for this market, which are capable of handling integrated circuits with line widths as narrow as 0.35 micron. Track's most advanced product line, the 90 Series, offers a proprietary wafer transfer system to increase throughput, features substantially improved contamination control specifications as compared to the Company's previous products and provides features allowing it to interface with factory automation systems. The Company believes it is the only manufacturer to offer a cluster which integrates its photolithography and photoresist products. In addition, the Track products are designed to interface with all stepper products in the industry. THERMCO SYSTEMS DIVISION designs, manufactures, markets and services large batch thermal products which address the oxidation/diffusion and LPCVD steps of the semiconductor fabrication process. Thermco products are used for a broad range of processing applications required in the fabrication of most semiconductor devices, including growing insulating layers on wafers, diffusing dopants into the silicon structure and depositing insulating or conducting films on the wafer surface. Thermco's products incorporate proprietary technology it has developed in the areas of thermal control, gas handling, particle control and automated wafer handling. Thermco offers a full range of both horizontal and vertical processing systems. The most advanced product currently offered by the Company is the Series 8000 Advanced Vertical Processor ("AVP"). The Series 8000 single tube systems include advanced process control, leading software for data acquisition and display, advanced automation, a proprietary process chamber design and an option for atmosphere control within the wafer handling area. 4 7 As part of its continuing commitment to work closely with its existing and potential customers, the Company has entered into business relationships with IBM, SEMATECH, Inc. ("SEMATECH"), Intel, Motorola and Texas Instruments pursuant to which these customers have made equity investments in, and SEMATECH has agreed to provide certain additional funding to, the Company. See "Business -- Business Relationships." Because of the highly technical nature of its products, the Company markets its products primarily through a direct sales force with sales, service and spare parts offices worldwide. The Company believes that its field service and process support capabilities are an important factor in its selection as an equipment supplier. Increasingly, semiconductor manufacturers are requiring seven-day, around the clock, on site or on call support. To meet this need, the Company is expanding its field service organization, increasing its technical and process support personnel and enhancing its training programs. Service personnel are based in field offices throughout the United States, Western Europe, Japan and the Pacific Rim and increasingly on site at particularly large customer locations. In addition, each customer has a single designated service account manager for all its support needs. The Company's principal executive office is located at 2240 Ringwood Avenue, San Jose, California 95131, and its telephone number is (408) 434-0500. 5 8 RISK FACTORS Prospective purchasers of Shares offered hereby should carefully consider the following risk factors in addition to the other information presented in this Prospectus. Cyclical Nature of the Semiconductor Industry. The semiconductor industry into which the Company sells its products is highly cyclical and has historically experienced periodic downturns, which often have had a severe effect on the semiconductor industry's demand for semiconductor processing equipment. Prior semiconductor industry downturns have resulted in significant reductions in the Company's net sales, gross margin and net income. For example, due in part to weakness in the semiconductor market, demand for the Company's semiconductor processing equipment declined during fiscal 1992 and the Company was not profitable for the year. While the Company has been profitable for the past 14 quarters, there is no assurance that the Company will be able to maintain profitability. Moreover, the Company's operations as a whole will continue to be dependent on the capital expenditures of semiconductor manufacturers, which in turn will be largely dependent on the current and anticipated market demand for integrated circuits and products utilizing integrated circuits. Any future weakness in demand in the semiconductor industry is likely to have a material adverse effect on the Company's business and results of operations. Uncertain Development of Market for Micrascan Products. The development of a market for the Company's Micrascan photolithography products will be highly dependent on the continued trend towards finer line widths in integrated circuits and the inability of traditional I-Line stepper manufacturers to keep pace with this trend through either enhanced technologies or improved processes. The market for the Company's Micrascan photolithography products has developed more slowly than the Company anticipated at the time the Company acquired SVGL in May 1990. From fiscal 1990 to fiscal 1993, SVGL sold an aggregate of 26 Micrascan systems, 20 of which were sold to IBM, a minority shareholder in SVGL, and three of which were sold to SEMATECH. In fiscal 1994 through the third quarter of fiscal 1995, SVGL shipped 14 Micrascan systems to six customers, of which eight were shipped in fiscal 1995. At June 30, 1995, SVGL had a backlog of 26 Micrascan units for shipment to eight global semiconductor manufacturers. While such orders are encouraging, they are not necessarily indicative of industry-wide acceptance of the Micrascan technology. The Company and many industry observers initially believed that I-Line steppers, the most advanced photolithography exposure equipment in widespread production use at the time the Company acquired SVGL, could not be modified to be capable of fabricating complex semiconductor devices with line widths of less than 0.5 micron, such as 64 and 256 megabit dynamic random access memories ("DRAMs"). Since 1990, however, stepper manufacturers have extended the capability of their I-Line steppers to 0.5 micron or finer line widths. The Company believes that, as a consequence, many manufacturers of complex devices are likely to continue to use steppers for fabricating such devices. The Company believes that as devices increase in size and complexity and require finer line widths, the technical advantages of Micrascan systems as compared to steppers will enable semiconductor manufacturers to achieve finer line widths, higher yields and increased throughput. The Company believes, however, that these larger and more complex devices will not be produced in volume until 1996 or 1997. It is possible that the demand for these larger and more complex devices, and the fabrication equipment to manufacture them, may never develop or may develop even later than 1997. The Company believes semiconductor manufacturers will not require production equipment as advanced as Micrascan until at least 1996, and that substantial sales of the Company's Micrascan systems will not begin until late 1996 or 1997, if at all. Stepper manufacturers have enhanced their machines in the past, and in the future may further enhance their machines to achieve finer line widths, sufficiently to erode Micrascan's expected yield, throughput and line width control advantages. If this occurs, demand for Micrascan systems may not develop as the Company expects. SVGL was not profitable in fiscal 1994 or the first two quarters of fiscal 1995 and was marginally profitable in the third quarter of fiscal 1995 and there can be no assurance that it will be able to operate profitably in the future. Failure of SVGL to achieve substantial sales of Micrascan systems or a delay in achieving such sales could have a material adverse effect on the Company's ability to continue to operate profitably. Fluctuations in Quarterly Operating Results. The Company has historically experienced substantial quarterly fluctuations in its operating results. Due to the relatively small number of systems sold during each fiscal quarter and the relatively high revenues per system, production or shipping delays or customer order rescheduling can significantly affect quarterly revenues and profitability. The Company has experienced and 6 9 may again experience quarters during which a substantial portion of the Company's net sales are realized near the end of the quarter. Accordingly, delays in shipments near the end of a quarter can cause quarterly net sales to fall significantly short of anticipated levels. Since most of the Company's expenses are fixed in the short term, such shortfalls in net sales could have a material adverse effect on the Company's business and results of operations. The Company's operating results may also vary from quarter to quarter based upon numerous factors including the timing of new product introductions, product mix, levels of sales, proportions of domestic and international sales, activities of competitors, acquisitions, international events and problems in obtaining adequate materials or components on a timely basis. Historically, gross margins in the Thermco and SVGL businesses have been lower than in the Track business. To the extent sales of Micrascan products, and to a lesser extent Thermco products, increase as a percentage of total net sales, the Company's overall gross margins may be unfavorably impacted. In light of these factors and the cyclical nature of the semiconductor industry, the Company expects to continue to experience variability in quarterly operating results. Need to Increase Manufacturing Capacity. The Company currently has insufficient manufacturing capacity to meet multiple customer demands for Micrascan products and is expanding its manufacturing capacity to meet current demand levels. The Company believes that its ability to supply systems in volume will be a major factor in customer decisions to commit to the Micrascan technology. Accordingly, the Company must initiate facility and capital improvements today to meet expected shipment volumes in 1997 and 1998. From time to time, the Company has experienced difficulty in ramping up production or effecting transitions to new products and, consequently, has suffered delays in product deliveries. There can be no assurance that the Company will not experience manufacturing problems as a result of capacity constraints or ramping up production by upgrading or expanding existing operations. Based upon its forecast of continued high growth for photolithography equipment, the Company has developed plans to increase its production capacity under an extremely aggressive expansion schedule. Successful execution of the Company's expansion will require timely identification and acquisition of appropriate sites, receipt of requisite approvals, construction and equipping of facilities, recruitment, training and retention of a high quality workforce and achievement of satisfactory manufacturing results on a scale greater than the Company's prior expansions. See "Use of Proceeds." There can be no assurance the Company can successfully manage this risk. This could result in product delivery delays and a subsequent loss of future revenues. In particular, the Company believes that protracted delays in delivering initial quantities of Micrascan products could result in semiconductor manufacturers electing to install competitive equipment in their advanced fabrication facilities, which could impede acceptance of the Micrascan products on an industry-wide basis. In addition, the Company's operating results could also be adversely affected by the increase in fixed costs and operating expenses related to increases in production capacity if net sales do not increase commensurately. Dependence on New Products and Processes; Importance of Timely Product Introductions and Enhancements. Semiconductor manufacturing equipment and processes are subject to rapid technological change. The Company believes that its future success will depend in part upon its ability to continue to enhance its existing products and their process capabilities and to develop and manufacture new products with improved process capabilities that enable semiconductor manufacturers to fabricate semiconductors more efficiently. Failure to introduce new products or enhancements in a timely manner could result in loss of competitive position and reduced sales of existing products. In particular, the Company believes that advanced logic devices and DRAMs will require increasingly finer line widths. As a consequence, it is important to develop and introduce a version of the Micrascan capable of exposing line widths of 0.25 micron by mid-1996. In addition, new product introductions could contribute to quarterly fluctuations in operating results as orders for new products commence and increase the potential for a decline in orders of existing products, particularly if new products are delayed. In the past, the Company has experienced significant delays in the introduction of certain of its products and product enhancements due to technical, manufacturing and other difficulties and may experience similar delays in the future. These difficulties may be exacerbated as the geometries of semiconductors continue to decrease. Furthermore, the inability to produce such products or any failure to achieve market acceptance could have a material adverse effect on the Company's business and results of operations. 7 10 Significant delays can occur between a product's introduction and the commencement by the Company of volume production of such product. There can be no assurance that the Company will be successful in the introduction and volume production of new and enhanced products or that the Company will be able to develop and introduce new and enhanced products and processes which satisfy a broad range of customer needs and achieve market acceptance. See "Business--Silicon Valley Group, Inc." and "-- Research and Development." Research and Development Funding; Certain Capital Commitments. The Company believes that in selecting a photolithography equipment manufacturer, customers look for a long term product development strategy and the ability to fund that development because photolithography exposure equipment can represent a substantial portion of the equipment cost of a fabrication facility. Semiconductor manufacturers may be unwilling to rely on a relatively small supplier such as the Company for a critical element of the fabrication process if the supplier does not have sufficient capital to implement its product development strategy. The Company depends in part on external sources to fund its photolithography development efforts and capital equipment expenditures. SEMATECH has entered into agreements with the Company to provide a portion of this funding, but there can be no assurance that the Company will be able to attain the milestones required by the agreements for such incremental funding or that SEMATECH will be capable of providing the agreed-upon funding, either of which could have an unfavorable impact on future photolithography development. If the Company achieves all milestones, the SEMATECH agreements provide for an additional $22 million of such funding during fiscal 1995, 1996 and 1997, all of which the Company expects would be an offset to its research and development expenditures. Through June 30, 1995, the Company had recognized approximately $7.7 million of this amount. Were the Company not to fulfill certain obligations under its agreement with SEMATECH, the Company could be required to repay all funds received under the agreements. In the event that the Company does not receive SEMATECH funding for any reason, it would be required to either curtail development of photolithography products or make up the shortfall from its own funds or other sources. If the Company was required to make up these funds, its research and development expenses would increase significantly and its operating income would be reduced correspondingly. See "Business -- Research and Development." The Company anticipates that it will need to continue to make substantial research and development expenditures, particularly in its photolithography products, in order to remain competitive in the semiconductor equipment industry. If the Company were not able to secure additional external funding or increase its revenues to support such research and development expenditures, its new product development and product enhancement efforts would be impaired, which would have a material adverse effect on the Company's results of operations. In part to address customer concerns about adequately capitalizing the photolithography business, the Company is obligated under its agreements with SEMATECH and with Intel Corporation, Motorola Inc. and Texas Instruments Incorporated (the "Investors") to commit funds to the development and production of Micrascan photolithography equipment, and a portion of the net proceeds of this offering may be used to satisfy these requirements. Under the terms of its agreement with SEMATECH, the Company is obligated to fund from its own resources not less than 120%, up to a maximum of $36 million over a three year period, of the total amount received from SEMATECH to further the development of Micrascan technology, to increase the manufacturing capability and capacity for Micrascan products and to fund related inventory costs. Under the terms of its agreements with the Investors, the Company is obligated to use the $30 million from the sale to the Investors of securities which have been converted into Common Stock, as well as an additional $25 million of Company funds at any time over a five year period, to fund increased Micrascan production capacity, increased research and development of the Micrascan technology, the purchase of additional capital equipment and to augment working capital for growth of the Micrascan photolithography operations. No assurance can be given that the Company will be able to obtain the necessary funding to meet its commitments under these agreements. The Company is obligated to invest these funds, regardless of the success of the project. As a result, the Company may be required to use its financial resources to comply with these commitments even if it believes that such resources would be better utilized in other areas. Were the 8 11 Company to breach any of its obligations under its agreement with the Investors, the Investors could cause the Company to repurchase their shares, which could have a material adverse effect on the Company. In connection with the Company's acquisition of SVGL in 1990, SVGL received an equity investment and research and development funding commitments for Micrascan from IBM and agreed to make future payments to IBM based on the ongoing operating results of SVGL. As part of a subsequent agreement with the Investors, IBM was also granted certain rights to purchase initial quantities of future generations of the Company's Micrascan products. See "Business -- Business Relationships." Customer Concentration. The Company relies on a limited number of customers for a substantial percentage of its net sales. In fiscal 1994, Intel, Motorola and SGS-Thomson represented 20%, 19% and 11%, respectively, of sales and the Company's largest five customers represented 58% of sales. For the first nine months of 1995, Intel, Motorola and SGS-Thomson represented 18%, 20% and 14%, respectively, of sales and the Company's largest five customers represented 64% of sales. In fiscal 1994 and the first nine months of fiscal 1995, Intel represented 45% and 38%, respectively, of Track sales. Track operations were responsible for a substantial portion of the Company's profits in both periods. The loss of a significant customer (and in particular the loss of Intel as a Track customer), a delay in shipment due to customer rescheduling or any substantial reduction in orders by a significant customer, including reductions in orders due to market, economic or competitive conditions in the semiconductor industry, could adversely affect the Company's business and results of operations. See "Business -- Customers." Competition. The semiconductor processing equipment industry is highly competitive. The Company faces substantial competition both in the United States and in other countries for all of its products. The trend toward consolidation in the semiconductor processing equipment industry has made it increasingly important to have the financial resources necessary to compete effectively across a broad range of product offerings, to fund customer service and support on a worldwide basis and to invest in both product and process research and development. Significant competitive factors include product performance, price and reliability, familiarity with each particular manufacturer's products, established relationships between suppliers and customers, particulate contamination control and product availability. While the Company believes that outside Japan and the Pacific Rim it competes favorably with respect to most of these factors, it has on occasion been subject to intense price competition with respect to particular orders and has had difficulty establishing new relationships with certain customers who have long-standing relationships with other suppliers. Certain of the Company's existing and potential competitors have substantially greater name recognition, financial, engineering, manufacturing and marketing resources and customer service and support capabilities than the Company. In addition, Nikon, and to a lesser extent Canon, have long established relationships as suppliers of photolithography equipment to most of the semiconductor manufacturers. Although the Company has supplied Track and Thermco equipment to many of these customers, it has not previously sold Micrascan photolithography equipment to them. Due to the Company's position in the photolithography market, an announcement of a new product by any of these large competitors may cause customers to delay purchases until the new product is introduced. See "-- Dependence on New Products and Processes; Importance of Timely Product Introductions and Enhancements" and "Business -- Competition." The Company believes that its competitors will continue to improve the design and performance of their current products and processes, and to introduce new products and processes with improved price and performance characteristics. For example, both Nikon and Canon have announced photolithography products using step and scan technology and a Deep UV illumination source, and Nikon has indicated that it expects to deliver production units in mid-1996. In addition, the Company believes that other potential competitors, including ASM Lithography, are developing step and scan technologies. There can be no assurance that the Company will be able to compete effectively in the future. Currency Fluctuations. Substantially all of the Company's manufacturing costs currently are incurred in the U.S., while a number of the Company's principal competitors' manufacturing costs are incurred in Japan. As a result, a substantial increase in the value of the U.S. dollar relative to the Japanese yen would put the Company at a competitive disadvantage, and would materially and adversely affect the Company's business and results of operations. 9 12 Importance of the Japanese and Pacific Rim Market. The Japanese and Pacific Rim market (including fabrication facilities operated outside these areas by Japanese and Pacific Rim semiconductor manufacturers) represent a substantial portion of the overall market for semiconductor equipment. To date, the Company has not been successful in securing an adequate share of these markets. The Company believes that the Japanese companies with which it competes have a competitive advantage because their dominance of the Japanese and Pacific Rim semiconductor equipment market provides them with the sales and technology base to compete more effectively throughout the rest of the world. The Company is not engaged in any collaborative effort with any Japanese or Pacific Rim semiconductor manufacturer regarding process and equipment development. As a result, the Company may be at a competitive disadvantage to the Japanese equipment suppliers which are engaged in such collaborative efforts with Japanese and Pacific Rim semiconductor manufacturers. There can be no assurance that the Company will be able to compete successfully in the future in Japan, the Pacific Rim or elsewhere in the world or that competitive pressures will not adversely affect the Company's results of operations. See "Business -- Competition." Termination of Canon Letter of Intent. In April 1993, the Company entered into a letter of intent with Canon, Inc. ("Canon"), a major Japanese company, for the purpose of establishing a worldwide strategic alliance based on SVGL's Micrascan technology. The Company and Canon were unable to reach agreement and the letter of intent expired on November 30, 1994. Although Canon is contractually prohibited until April 2003 from manufacturing a specifically defined step and scan photolithography machine or disclosing related information, Canon could introduce a product that includes certain step and scan technology without violating this prohibition. As a result of the expiration of the letter of intent, the Company believes that Canon has accelerated its previously suspended development of a step and scan photolithography product which will compete with Micrascan. See " -- Uncertain Development of Market for Micrascan Products," and "Business -- Competition." Patents and Licenses. As is typical in the semiconductor equipment industry, the Company has from time to time received, and may in the future receive, communications from third parties asserting patents or copyrights on certain of the Company's products and technologies. At least one of the Company's customers has put the Company on notice that it has received a notice of infringement from Jerome H. Lemelson, alleging that equipment used in the manufacture of electronic devices infringes patents issued to Mr. Lemelson relating to "machine vision" or "barcode reader" technologies. The customer has put the Company on notice it intends to seek indemnification from the Company for any damages and expenses resulting from this matter if found liable or if the customer settles the claim. The Company cannot predict the outcome of this or any similar claim or its effect upon the Company, and there can be no assurance that any such litigation or claim would not have a material adverse effect upon the Company's financial condition or results of operations. Dependence on Key Employees. The Company's future success is dependent upon its ability to attract and retain qualified management, technical, sales and support personnel. The competition for such personnel is intense. The loss of certain key people or the Company's inability to attract and retain new key employees could materially adversely affect the Company's business and results of operations. Dependence on Sole or Limited Source Suppliers. Certain of the raw materials, components and subassemblies included in the Company's products are obtained from single sources or a limited group of suppliers. Although the Company seeks to reduce its dependence on these sole and limited source suppliers, disruption or termination of certain of these sources could occur and such disruptions could have at least a temporary adverse effect on the Company's business and results of operations. Moreover, a prolonged inability to obtain certain components could have a material adverse effect on the Company's business and results of operations and could result in damage to customer relationships. Volatility of Stock Price. The public offering price of the Common Stock offered hereby may not be indicative of prices that will prevail in the trading market for the Common Stock. The stock market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. In addition, the market price of the Company's Common Stock has been and is likely to be highly volatile. Factors such as fluctuations in the Company's operating results, shortfalls in revenue or earnings from levels expected by securities analysts, announcements of technological 10 13 innovations or new products by the Company or its competitors, governmental regulation, developments with respect to patents or proprietary rights and litigation relating thereto and general market conditions may have a significant adverse effect on the market price of the Common Stock. See "Price Range of Common Stock." Shares Eligible for Future Sale. After completion of this offering, the Company will have approximately 28,720,921 shares of Common Stock outstanding, of which 27,140,440 shares will be freely tradeable without restriction. The Company's executive officers and directors beneficially own 393,075 shares of Common Stock, which includes 306,894 shares issuable upon exercise of options. Such shares will be restricted from sales until 90 days after this offering pursuant to agreements with the Underwriters. Thereafter, such shares can be sold in the public market subject to certain volume and other resale restrictions of Rule 144 under the Securities Act. In addition, SEMATECH holds a warrant, expiring on September 30, 1998, to purchase 1,750,000 shares at $13.625 per share. The warrant is subject to a net exercise provision which permits the holder of the warrant to make a cashless exercise of the warrant based on the closing price of the Common Stock. Such cashless exercise would result in the issuance to SEMATECH of 1,209,631 shares of the Company's Common Stock (assuming a price per share of $44.125). In connection with the exercise of certain registration rights held by SEMATECH, the Company will, prior to November 24, 1995, register such shares. SEMATECH has agreed that it will not, without the prior written consent of Morgan Stanley & Co. Incorporated, sell or otherwise dispose of these shares from the date of the offering until February 19, 1996. After February 19, 1996, SEMATECH could sell that number of shares freely in the open market. The Company has registered for resale the 1,494,300 shares of Common Stock issued upon conversion of the Series B Preferred Stock held by the Investors. The Investors have agreed that they will not, without the prior written consent of Morgan Stanley & Co. Incorporated, sell or otherwise dispose of these shares from the date of the offering until February 19, 1996. After February 19, 1996, the Investors could sell the 1,494,300 shares freely in the market. Sales of a substantial number of shares in the public market could adversely affect the market price of the Common Stock and the Company's ability to raise additional capital at a price favorable to the Company. See "Underwriters." USE OF PROCEEDS The net proceeds to be received by the Company from the sale of the 3,500,000 shares of Common Stock offered by the Company hereby are estimated to be $147,717,000 ($169,927,000 if the Underwriters' over-allotment option is exercised in full). The Company intends to use the proceeds of this offering to purchase capital equipment, expand manufacturing facilities and to finance its working capital requirements and research and development activities, primarily in its lithography business to meet actual and anticipated demand for its Micrascan products. A portion of the net proceeds will be used for general corporate purposes and a portion may also be used for future acquisitions of complementary businesses or product lines as such opportunities may arise, although no such acquisitions are currently pending or in negotiation. Pending such applications, the net proceeds from this offering will be invested in bank deposits and short-term and medium-term investment grade, interest bearing securities. 11 14 PRICE RANGE OF COMMON STOCK The following table sets forth the range of high and low sales prices of the Company's Common Stock for the indicated periods, as reported by The Nasdaq National Market. On September 7, 1995, the last reported sale price for the Common Stock on The Nasdaq National Market was $44.125 per share. As of June 30, 1995, there were approximately 599 holders of record of the Common Stock.
HIGH LOW ---- ---- Fiscal year ended September 30, 1993: First Quarter........................................... $7 1/4 $4 1/2 Second Quarter.......................................... 8 5/8 6 Third Quarter........................................... 11 1/8 6 1/8 Fourth Quarter.......................................... 12 7/8 9 3/8 Fiscal year ended September 30, 1994: First Quarter........................................... 12 1/8 9 1/4 Second Quarter.......................................... 13 3/8 9 1/2 Third Quarter........................................... 12 3/8 9 1/4 Fourth Quarter.......................................... 14 7/8 11 3/8 Fiscal year ending September 30, 1995: First Quarter........................................... 21 1/4 14 Second Quarter.......................................... 30 3/4 18 3/8 Third Quarter........................................... 37 1/8 24 7/8 Fourth Quarter (through September 7, 1995).............. 49 3/8 35 5/8
DIVIDEND POLICY To date the Company has not declared or paid cash dividends on its Common Stock. The Board of Directors of the Company presently intends to retain all earnings for use in the Company's business and therefore does not anticipate declaring or paying any cash dividends on its Common Stock in the foreseeable future. The Company's revolving credit facility prohibits the payment of cash dividends of more than an aggregate of $5,000,000 per year on Common Stock. 12 15 CAPITALIZATION The following table sets forth, on an unaudited basis, the actual short-term debt and capitalization of the Company at June 30, 1995 and as adjusted to give effect to the sale by the Company of the 3,500,000 shares of Common Stock offered hereby, and the application of the net proceeds therefrom.
AS OF JUNE 30, 1995 ------------------------ ACTUAL AS ADJUSTED -------- ----------- (IN THOUSANDS, EXCEPT SHARE AMOUNTS) Short-term debt and current portion of long-term debt................. $ 877 $ 877 ======== ========= Long-term debt and capital leases..................................... $ 874 $ 874 Minority interest in SVGL............................................. 3,805 3,805 Stockholders' equity: Common Stock, $0.01 par value, 40,000,000 shares authorized; 25,071,565 shares outstanding actual; 28,571,565 shares outstanding as adjusted(1)................................................... 244,134 391,851 Retained earnings................................................... 86,561 86,561 -------- ----------- Total stockholders' equity..................................... 330,695 478,412 -------- ----------- Total capitalization........................................ $335,374 $ 483,091 ======== =========
--------------- (1) Excludes (i) as of August 31, 1995, 1,534,750 shares issuable upon exercise of outstanding options at an average exercise price of $16.82 per share and (ii) 1,750,000 shares issuable upon exercise of a warrant with an exercise price of $13.625 per share. 13 16 SELECTED CONSOLIDATED FINANCIAL DATA The selected consolidated financial data presented below as of September 30, 1993 and 1994 and for each of the years in the three year period ended September 30, 1994 have been derived from the consolidated financial statements of the Company, which have been audited by Deloitte & Touche LLP, independent auditors, which financial statements are incorporated by reference herein. The selected consolidated financial data as of September 30, 1990, 1991 and 1992 and for each of the years in the two-year period ended September 30, 1991 have also been derived from audited consolidated financial statements of the Company but which are not incorporated by reference herein. The selected consolidated financial data presented below as of June 30, 1995, and for the nine-month periods ended June 30, 1994 and 1995, and for each of the seven quarters in the period ended June 30, 1995, have been derived from unaudited consolidated financial statements of the Company. In the opinion of the Company's management, such unaudited consolidated financial data include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth therein. The following consolidated financial data should be read in conjunction with the consolidated financial statements, related notes and other financial information incorporated by reference herein. See "Incorporation of Certain Documents by Reference."
NINE MONTHS ENDED FISCAL YEAR ENDED SEPTEMBER 30, JUNE 30, -------------------------------------------------------- -------------------- 1990(1) 1991 1992 1993 1994 1994 1995 -------- -------- -------- -------- -------- -------- -------- (IN THOUSANDS, EXCEPT PER SHARE DATA) CONSOLIDATED INCOME STATEMENT DATA: Net sales............................... $184,289 $234,798 $192,457 $240,633 $319,922 $237,942 $323,073 Cost of sales........................... 110,441 149,337 115,296 147,207 195,511 145,726 196,177 -------- -------- -------- -------- -------- -------- -------- Gross profit............................ 73,848 85,461 77,161 93,426 124,411 92,216 126,896 Research, development and related engineering........................... 25,292 30,004 27,009 26,332 30,443 22,675 28,189 Marketing, general and administrative... 40,287 50,661 48,544 59,710 67,517 50,303 64,523 -------- -------- -------- -------- -------- -------- -------- Operating income........................ 8,269 4,796 1,608 7,384 26,451 19,238 34,184 Interest and other income (expense), net................................... (342) (1,458) (44) (464) 369 (50) 4,698 -------- -------- -------- -------- -------- -------- -------- Income before income taxes and minority interest.............................. 7,927 3,338 1,564 6,920 26,820 19,188 38,882 Provision (credit) for income taxes..... 3,106 (781) 1,089 2,076 10,191 7,675 13,998 Minority interest....................... 372 2,478 767 359 (135) (267) 23 -------- -------- -------- -------- -------- -------- -------- Net income (loss)....................... $ 4,449 $ 1,641 $ (292) $ 4,485 $ 16,764 $ 11,780 $ 24,861 ======== ======== ======== ======== ======== ======== ======== Preferred Stock dividend................ -- -- $ 209 $ 1,190 $ 1,190 $ 893 $ 537 ======== ======== ======== ======== ======== ======== ======== Net income (loss) per common share...... $ 0.42 $ 0.12 $ (0.03) $ 0.22 $ 0.84 $ 0.60 $ 1.04 ======== ======== ======== ======== ======== ======== ======== Shares used in per share computations... 10,708 13,166 14,754 15,277 18,538 18,212 23,973 ======== ======== ======== ======== ======== ======== ========
AS OF JUNE AS OF SEPTEMBER 30, 30, -------------------------------------------------------- ------------ 1990 1991 1992 1993 1994 1995 -------- -------- -------- -------- -------- ------------ (IN THOUSANDS) CONSOLIDATED BALANCE SHEET DATA: Cash and equivalents........................... $ 30,699 $ 34,070 $ 32,743 $ 17,617 $ 87,829 $194,472 Working capital................................ 60,403 84,959 93,084 110,512 173,303 312,068 Property and equipment, net.................... 33,686 28,994 26,861 18,664 13,313 19,638 Total assets................................... 183,423 192,317 180,777 212,284 271,674 471,702 Short-term debt and current portion of long-term debt............................... 4,367 2,043 4,407 14,971 828 877 Long-term debt and capital leases.............. 26,533 8,200 1,652 2,338 1,510 874 Retained earnings.............................. 42,927 44,568 43,651 46,946 62,237 86,561 Stockholders' equity........................... 70,234 103,800 121,116 126,997 185,215 330,695
--------------- (1) Includes the results of operations of SVGL from May 1, 1990. 14 17 The following table presents unaudited quarterly results in dollar amounts and as a percentage of net sales for the last seven quarters.
FISCAL 1994 FISCAL 1995 ----------------------------------------- ------------------------------- DEC. 31 MAR. 31 JUNE 30 SEPT. 30 DEC. 31 MAR. 31 JUNE 30 ------- ------- ------- -------- ------- -------- -------- CONSOLIDATED INCOME STATEMENT DATA: Net sales....................................... $70,917 $85,300 $81,725 $81,980 $85,971 $109,380 $127,722 Cost of sales................................... 43,859 52,876 48,991 49,785 52,769 67,849 75,559 ------- ------- ------- -------- ------- -------- -------- Gross profit.................................... 27,058 32,424 32,734 32,195 33,202 41,531 52,163 Research, development and related engineering... 6,546 7,675 8,454 7,768 8,278 9,816 10,095 Marketing, general and administrative........... 15,836 16,951 17,516 17,214 17,622 21,088 25,813 ------- ------- ------- -------- ------- -------- -------- Operating income................................ 4,676 7,798 6,764 7,213 7,302 10,627 16,255 Interest and other income (expense), net........ (252 ) 36 166 419 1,053 996 2,649 ------- ------- ------- -------- ------- -------- -------- Income before income taxes and minority interest...................................... 4,424 7,834 6,930 7,632 8,355 11,623 18,904 Provision for income taxes...................... 1,770 3,132 2,773 2,516 3,008 4,184 6,806 Minority interest............................... (65 ) (40 ) (162 ) 132 17 (48) 54 ------- ------- ------- -------- ------- -------- -------- Net income...................................... $2,719 $4,742 $4,319 $ 4,984 $5,330 $ 7,487 $ 12,044 ======= ======= ======= ======= ======= ======== ======== Preferred Stock dividend........................ $ 298 $ 297 $ 298 $ 297 $ 298 $ 239 $ -- ======= ======= ======= ======= ======= ======== ======== Net income per common share..................... $ 0.15 $ 0.23 $ 0.21 $ 0.24 $ 0.25 $ 0.33 $ 0.45 ======= ======= ======= ======= ======= ======== ======== Shares used in per share computations........... 16,400 19,032 19,205 19,515 20,322 22,811 26,968 ======= ======= ======= ======= ======= ======== ========
AS A PERCENTAGE OF NET SALES ---------------------------------------------------------------------------- Net sales....................................... 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% Cost of sales................................... 61.8 62.0 59.9 60.7 61.4 62.0 59.2 ------- ------- ------- -------- ------- -------- -------- Gross profit.................................... 38.2 38.0 40.1 39.3 38.6 38.0 40.8 Research, development and related engineering... 9.2 9.0 10.3 9.5 9.6 9.0 7.9 Marketing, general and administrative........... 22.3 19.9 21.4 21.0 20.5 19.3 20.2 ------- ------- ------- -------- ------- -------- -------- Operating income................................ 6.6 9.1 8.3 8.8 8.5 9.7 12.7 Interest and other income (expense), net........ (0.4 ) -- 0.2 0.5 1.2 0.9 2.1 ------- ------- ------- -------- ------- -------- -------- Income before income taxes and minority interest...................................... 6.2 9.2 8.5 9.3 9.7 10.6 14.8 Provision for income taxes...................... 2.5 3.7 3.4 3.1 3.5 3.8 5.3 Minority interest............................... (0.1 ) -- (0.2 ) 0.2 -- -- -- ------- ------- ------- -------- ------- -------- -------- Net income...................................... 3.8% 5.6% 5.3% 6.1% 6.2% 6.8% 9.4% ======= ======= ======= ======= ======= ======== ========
15 18 BUSINESS SVG designs, manufactures, markets and services semiconductor fabrication equipment for the worldwide semiconductor industry. The Company has three principal product groups which focus primarily on photolithography, photoresist processing, and deposition for oxidation/diffusion and LPCVD. The Company's products incorporate proprietary technologies and unique processes, and focus on providing process and product technologies and productivity enhancements to its customers. The Company believes that its Micrascan step and scan photolithography exposure system, which utilizes a Deep UV light source allowing line widths of 0.35 micron and below, is the most technologically advanced machine currently being shipped in quantity to global semiconductor manufacturers. SVG supports its reliable, cost-effective products through a network of worldwide service and technical support organizations. The Company's customers consist of leading semiconductor manufacturers including Analog Devices, Cypress Semiconductor, Hewlett-Packard, Intel, IBM, LG Semicon, Loral, Motorola, Philips Semiconductor, SGS-Thomson, Samsung, Siemens, Symbios Logic and Texas Instruments. INDUSTRY BACKGROUND Continuous improvements in semiconductor process and design technologies have led to the production of smaller, more complex and more reliable devices at a lower cost per function. As performance has increased and size and cost have decreased, the demand for semiconductors has expanded beyond the primary market in computer systems to include applications in telecommunications systems, automotive products, consumer goods and industrial automation and control systems. Semiconductor content as a percentage of system cost has also increased. In addition, the demand for electronic systems has expanded geographically with the emergence of new markets, particularly in the Pacific Rim. Consequently, semiconductor sales have increased significantly over the long term (growing at a compound rate of approximately 16% from 1983 to 1993) but have experienced significant variation in growth rates. The Company believes that these long-term trends will continue and will be accompanied by a growing demand for semiconductor production equipment that can produce advanced integrated circuits in high volumes at the lowest cost of ownership. The rapid development of advanced semiconductor applications requires semiconductor manufacturers to continually improve their core technology and manufacturing capabilities to remain competitive within the industry. As a consequence, semiconductor manufacturers demand increasingly sophisticated, cost effective processing equipment from semiconductor equipment suppliers. The increasing diversity and complexity of semiconductor products, the demands of technological change and the costs associated with keeping pace with industry developments have contributed to the emergence of cooperative development and manufacturing alliances with semiconductor equipment suppliers. The Company believes it is essential to have customer alliances to provide access to valuable product and process technologies. These factors result in customers concentrating their business with a small number of key suppliers. SILICON VALLEY GROUP, INC. SVG designs and manufactures sophisticated semiconductor manufacturing systems for advanced fabrication facilities. The Company has three principal product groups which focus on photolithography, photoresist processing and deposition for oxidation/diffusion and LPCVD. SVG believes that its Micrascan step and scan photolithography exposure system, which utilizes a Deep UV light source allowing line widths of 0.35 micron and below, is the most technologically advanced machine currently being shipped in quantity to global semiconductor manufacturers. The Company's products incorporate proprietary technologies and unique processes, and focus on providing process and product technologies and productivity enhancements to customers. SVG's products are based on proprietary technologies in photolithography, control software, optics, and particulate control. The Company's objective is to strengthen its position as a leading worldwide semiconductor equipment supplier by offering a broad line of technologically advanced products and expending substantial resources on research and development to create new, innovative products and processes. The Company has close working relationships with leading semiconductor manufacturers so that it may design its products in conjunction with 16 19 the development of the semiconductor manufacturers' advanced processes. SVG works closely with its existing and potential customers, industry consortia and research institutions to improve current products and processes and to define new product development opportunities. These efforts enable the Company to participate in the development of new technologies, to influence the design of new fabrication processes and to position itself as a principal supplier for volume equipment orders. The Company supports its reliable, cost-effective products through a network of worldwide service and technical support organizations. SVG believes that these strategies, together with its current market position and product portfolio, will enable the Company to enhance its position as a leading global semiconductor equipment supplier. SVG's business is organized into three principal product groups. The Company manufactures and markets its photolithography exposure products through SVGL, its photoresist processing products through Track and its oxidation/diffusion and LPCVD products through Thermco. SVG LITHOGRAPHY SYSTEMS, INC. SVGL designs, manufactures, markets and services advanced photolithography exposure systems. Photolithography is one of the most critical and expensive steps in integrated circuit fabrication, representing approximately one-third of the fabrication cost. Consequently, integrated circuit manufacturers focus on obtaining photolithography equipment to help them produce increasingly complex devices reliably, efficiently and cost-effectively. In the photolithography step of the fabrication process, the integrated circuit patterns are projected through masks, or reticles, onto the silicon wafers. As semiconductors have become more complex, the patterns have become finer, with line widths as narrow as 0.35 micron (approximately 15 millionths of an inch) in many of today's more advanced integrated circuits. As the patterns become finer, photolithography exposure systems must be capable of projecting the patterns through the masks with ever finer resolution. The resolution capability of a photolithography exposure system is a function of its depth of focus, numerical aperture (a measure of its light gathering characteristics) and the wavelength of the light used in pattern projections. Historically, there have been two major approaches to photolithographic exposure systems: full field scanners and conventional refractive systems. The full field scanners project a full scale mask image onto full wafers while the refractive systems (steppers) sequentially expose small sections of a wafer in a stepped sequence of exposures, but do so by reducing the size of a mask image by several fold (typically 5 times). Thus, scanners offer large exposure fields while steppers offer masks that are easier to make and have a lower cost. These strengths are combined in the step and scan system. Other trends are the reduction in wavelength from G-line (436 nanometer) to I-line (365 nanometer) to Deep UV (248-193 nanometer) and the increase in numerical aperture from 0.2 to 0.6. Micrascan. The Company believes that its Micrascan photolithography exposure system provides the greater resolution required for the next generation of complex, fine geometry integrated circuits through its use of a Deep UV light source and overcomes the throughput, yield and line-width limitations of steppers by combining the elements of both steppers and scanners into the Micrascan's "step and scan" technology. The Micrascan combines advantages of scanning projection aligners and steppers by scanning only a portion of the wafer, then "stepping" to another portion of the wafer and repeating the process as necessary. Each scan has the capability to expose a larger segment of the wafer, or "field," than a stepper can expose in a single step. The large exposure field enables Micrascan to fabricate larger devices in a single scan than steppers, thus avoiding the necessity of "stitching" a circuit together through two different exposures. In addition, Micrascan continuously modifies the position of the wafer surface during the scan to keep the wafer in the optimal focal plane, thereby providing Micrascan a larger usable depth of focus field than steppers. The larger the usable depth of focus field is, the more tolerant of variations in the wafer surface the equipment will be. The Company believes Micrascan's greater tolerance of wafer surface variations can reduce the number of defective devices on a wafer, thereby contributing to higher yields. Scanning across the field instead of exposing the entire field at one time also enables Micrascan to achieve greater uniformity of resolution across the entire exposure field and contributes to higher yields. 17 20 The Company believes that SVGL has substantial technological expertise and process knowledge in developing Deep UV step and scan photolithography systems. SVGL has developed internal capability to design and fabricate optical lenses, mirrors and coatings. This includes its own proprietary optical metrology using phase measuring interferometry to precisely measure and test the optical elements it produces. Micrascan incorporates both mirrors and lenses in its optical system, which the Company believes allows for a higher power optical projection system, is less sensitive to environmental variants and accommodates the use of light sources with broader spectral bandwidth (than refractive optics) with the benefits of reduced running cost and increased reliability. In addition to the optical system technology described above, SVGL has developed certain proprietary mechanical systems incorporated in the Micrascan to control the alignment of the wafer and the reticles prior to and during the wafer exposure step. These alignment systems contribute to the Micrascan's ability to scan the exposure field at speeds of 50mm per second or greater with no significant loss of resolution, thereby increasing the throughput capability of the machine. The Company believes that many of the more complex semiconductor devices currently under development, such as the most advanced microprocessors and DRAMs, fit within the larger exposure field scanned by the Micrascan but do not fit within the exposure field of the most advanced steppers currently in widespread production use. In addition, these more complex devices feature increasingly narrow line widths, which require greater resolution in exposing the photoresist. The Company believes that, as these larger and more complex logic and memory devices move from development to production, the technical advantages of Deep UV step and scan systems over existing I-Line steppers will provide a greater incentive to semiconductor manufacturers to purchase step and scan systems rather than steppers in order to achieve higher yields, faster throughput and more precise line-width control. The Company believes, however, that these devices will not be produced in volume until late 1996 or 1997. The Micrascan systems which the Company is now shipping in volume sell for up to approximately $4,500,000, depending upon configuration. Micralign. SVGL also sells a family of scanning projection aligners known as "Micralign." The most advanced product in this family, the Micralign 700, is used primarily in the production of semiconductor devices with minimum feature sizes above 1.25 microns, or in the fabrication of less critical layers within more sophisticated semiconductor devices. Micralign products, which have historically accounted for a significant portion of the revenues of SVGL, are a mature product family. Sales of Micralign products have declined in recent years as steppers have supplanted projection aligners. Even with the current upturn in the semiconductor industry and the resulting expansion of existing facilities, the Company anticipates that such a decline in sales will continue. A large installed base of Micralign systems exists throughout the world and a majority of SVGL's Micralign related revenues is derived from servicing that installed base and the sales of spare parts and refurbished systems. The list price of the Micralign 700 is approximately $995,000 and refurbished Micralign systems sell for lesser amounts. TRACK SYSTEMS DIVISION Track designs, manufactures, markets and services photoresist processing equipment which performs all the steps necessary to process semiconductor wafers prior to photolithography exposure, including cleaning, adhesion promotion and photoresist coating, and which performs all the steps required to treat wafers after photolithography exposure prior to etching, including developing and baking. As photoresist processing technology has evolved, SVG has developed increasingly advanced product lines for this market, which are capable of handling integrated circuits with line widths as narrow as 0.35 micron. Each product line includes the principal processing capabilities described above and is generally sold in customer-specified configurations that can include specially engineered features and capabilities. All of the Track products are available in fully automated cassette-to-cassette configurations either as stand-alone processing stations or as in-line integrated manufacturing systems. The equipment is modular in design to allow configuration to customer requirements. Each semiconductor manufacturer may require certain of the processing stations to effect its proprietary or specialized processes. SVG believes it is the only manufacturer to offer a cluster which integrates its photolithography and photoresist products. In addition, Track products are designed to interface with all stepper products in the industry. 18 21 Track offers three product lines, each corresponding to the development of successive generations of wafer processing technologies. In general, it has been the Company's experience that introduction of new Track products has been followed by lower order levels for older products. 90 Series. The 90 Series photoresist processing system is designed for use in advanced fabrication processes for integrated circuits with line widths as narrow as 0.35 micron, such as is required for 64 and 256 megabit DRAMs. The 90 Series incorporates a proprietary wafer transfer system to increase throughput, features substantially improved contamination control specifications as compared to the Company's previous products and provides features allowing it to interface with factory automation systems, such as those using automated guided vehicles. The 90 Series can process wafers up to eight inches in diameter. In June 1992, an additional model of the 90 Series, the 90-S, was introduced. The 90-S requires less floor space and, in certain applications, may provide greater productivity than a conventional 90 Series system. Prices of the 90 Series range from approximately $650,000 to $1,500,000. 8800 Series. The 8800 Series is designed to meet market needs for photoresist contamination control and photoresist processing down to 0.8 micron line widths. The 8800 Series incorporates such automation features as beltless wafer handling, compatibility with low contamination wafer storage and movement techniques, advanced software and communications capabilities and certain process control improvements. The 8800 Series can process wafers from three to six inches in diameter. Prices of the 8800 Series range from approximately $350,000 to $750,000. 8600 Series. The 8600 Series is a belt-based wafer transport system capable of processing wafers with diameters of three to six inches and of supporting the needs of photoresist processing down to 1.0 micron line widths. The 8600 Series is typically purchased for expansion of current fabrication capacity. Prices of the 8600 Series range from approximately $200,000 to $400,000. THERMCO SYSTEMS DIVISION Thermco designs, manufactures, markets and services large batch thermal products which address the oxidation/diffusion and LPCVD steps of the semiconductor fabrication process. Thermco products are used for a broad range of processing applications required in the fabrication of most semiconductor devices, including growing insulating layers on the wafers, diffusing dopants into the silicon structure and depositing insulating or conducting films on the wafer surface. Thermco's products incorporate proprietary technology it has developed in the areas of thermal control, gas handling, particle control and automated wafer handling. There are two major configurations of thermal processing equipment, commonly referred to as vertical and horizontal, corresponding to the orientation of their reaction chamber(s). Vertical processing systems represent an increasing portion of the market for oxidation/diffusion and LPCVD processing equipment. Vertical reactors generally consist of a single, fully automated cylindrical reaction chamber, individually controlled by a dedicated computer control system. Vertical systems generally provide greater process uniformity and lower particle contamination than do horizontal systems, due to improved thermal control and an increased ability to maintain environmental integrity, thereby achieving higher yields in wafer processing. Additionally, vertical systems provide more flexibility in manufacturing configurations. Horizontal thermal processing systems, which are typically much larger and less automated than vertical reactors, were the standard of the semiconductor processing equipment industry and are still used for a broad range of processes. Series 8000 Advanced Vertical Processor ("AVP"). Initially shipped in September 1992, the AVP is a vertical furnace designed to meet the eight inch wafer requirements of sub-half micron processing. The Series 8000 single tube systems include advanced process control, data acquisition software, advanced automation, a proprietary process chamber design and an option for atmospheric control within the wafer handling area. SVG has incorporated design improvements to address shortcomings of the initial production units. Although the Company recently began shipping units to customers that it believes satisfy these shortcomings, no assurance can be given that these improved products will be successful in meeting customer requirements. The typical price range of an AVP system is $700,000 to $1,000,000 depending on process configuration. 19 22 Vertical Thermal Reactor ("VTR"). Thermco's VTR processes wafers from 100mm to 200mm in diameter. It operates under computer control, providing specialized process recipe introduction, cassette-to-cassette automation, monitoring of critical system functions and automated loading of wafers into the reaction chamber. In general, the VTR offers comparable reliability, lower contamination and better process uniformity than horizontal reactors. The VTR can be installed through-the-wall in a customer's clean room facility and is compatible with industry standard software interfaces. During fiscal 1994, SVG began shipping an enhanced version of VTR 7000PLUS. The enhanced VTR 7000PLUS offers improved process control, uniformity, reduced particle levels, higher throughput, internal storage capabilities and the industry's standard mechanical interface (SMIF). The typical price for the Company's VTR products is approximately $500,000 to $900,000. Horizontal Processing Systems. The typical horizontal system consists of four separately controlled cylindrical reaction chambers which are mounted horizontally, one directly above the other. Horizontal systems are a mature product family. Sales of these systems have been declining in recent years, as semiconductor manufacturers have increasingly installed vertical reactors in their newer fabrication facilities. Thermco expects this decline to continue despite the current capacity expansion being undertaken by semiconductor manufacturers. However, manufacturers of less complex devices will continue to have some need for horizontal processing systems for the foreseeable future. In addition, a large installed base of horizontal processing systems enables the Company to generate revenues through the sale of spare parts, upgrades and retrofits to the installed customer base. Prices for horizontal systems range from approximately $400,000 to $900,000. CUSTOMERS By working closely with its established customer base, SVG is able to identify new product development opportunities. Repeat sales to existing customers represent a significant portion of the Company's processing equipment sales. The Company believes that its installed customer base represents a significant competitive advantage. SVG's major semiconductor customers during the first nine months of fiscal 1995 included the following: Analog Devices LG Semicon Samsung Cypress Semiconductor Loral Siemens Hewlett-Packard Motorola Symbios Logic Intel Philips Semiconductor Texas Instruments IBM SGS-Thomson
The Company relies on a limited number of customers for a substantial percentage of its net sales. See "Risk Factors -- Customer Concentration." In fiscal 1994 and for the first nine months of fiscal 1995 Intel, Motorola and SGS-Thomson represented 20%, 19% and 11%, respectively, and 18%, 20% and 14%, respectively, of sales. The Company's top five customers represented 58% and 64% of the sales for fiscal 1994 and the first nine months of fiscal 1995, respectively. In fiscal 1993, 1994 and the first nine months of fiscal 1995 Intel represented 39%, 45% and 38%, respectively, of Track sales. Track operations were responsible for a substantial portion of SVG's profits in all three periods. BUSINESS RELATIONSHIPS In connection with its acquisition of SVGL in 1990, the Company entered into agreements with IBM pursuant to which IBM made a $3 million equity investment in SVGL and has funded approximately $17 million of ongoing research and development for the Company's Micrascan product line. The agreements with IBM require the Company to make future payments to IBM based on ongoing operating results of SVGL. Additionally, in connection with its agreements with the Investors, the Company agreed to provide IBM with certain rights to purchase initial quantities of future generations of the Company's Micrascan product. In 1994, the Company entered into an agreement with SEMATECH pursuant to which SEMATECH made an $8 million equity investment in the Company and agreed to provide up to $22 million of additional funding for SVGL development efforts and capital equipment expenditures. As part of its continuing commitment to work closely with its existing and potential customers, in February 1995 the Company entered into agreements with the Investors, pursuant to which these investors purchased, in equal 20 23 amounts, an aggregate of $30 million of the Company's capital stock and received certain rights to purchase initial quantities of future generations of the Company's Micrascan products. The Company has used the proceeds of these investments, together with additional Company funds, to increase Micrascan production, to further Micrascan research and development, to purchase additional capital equipment for SVGL and to augment working capital for growth of the Company's Micrascan photolithography operations. SALES, SERVICE AND SUPPORT Because of the highly technical nature of its products, SVG markets its products primarily through a direct sales force with sales, service and spare parts offices worldwide. The Company believes that its field service and process support capabilities are an important major factor in its selection as an equipment supplier. Increasingly, semiconductor manufacturers are requiring seven-day, around the clock, on site or on call support. To meet this need, SVG is expanding its field service organization, increasing its technical and process support personnel, enhancing its training programs and increasing spare part inventories deployed at both customer sites and regional field depots. Service personnel are based in field offices throughout the United States, Western Europe, Japan and the Pacific Rim and increasingly on site at particularly large customer locations. In addition, each customer has a single designated service account manager for all its support needs. BACKLOG At June 30, 1995, the Company had a backlog of approximately $348,000,000, which included 26 Micrascan units from eight customers. Backlog increased from approximately $146,000,000 at September 30, 1993 to approximately $209,000,000 at September 30, 1994 as a result of substantial increases in orders for SVGL and Thermco products. The Company includes in backlog only those orders to which a purchase order number has been assigned by the customer and for which delivery has been specified within 12 months. Such orders are subject to cancellation by the customer with limited charges. Because of the possibility of customer changes in delivery schedules, cancellation of orders and potential delays in product shipments, the Company's backlog as of any particular date may not be representative of actual sales for any succeeding period. RESEARCH AND DEVELOPMENT The market served by the Company is characterized by rapid technological change. Accordingly, the Company's product and process development programs are devoted to the development of new systems and processes, including new generations of products for existing markets, enhancements and extensions of existing products and custom engineering for specific customers. The Company believes that its future success will depend, in part, upon its ability to successfully introduce and manufacture new and enhanced, cost effective products, which satisfy a broad range of customer needs and achieve market acceptance. Accordingly, the Company works closely with semiconductor manufacturers, industry consortia, and research institutions to respond to the industry's evolving product and process requirements. The Company's research staff collaborates with key customers in order to evaluate designs, specifications and prototypes of the Company's new products. On September 30, 1994, SEMATECH, as part of an overall funding agreement, purchased warrants for $8,204,000 under which SEMATECH has the right to purchase 1,750,000 shares at $13.625 per share. The warrant is subject to a net exercise provision which permits the holder of the warrant to make a cashless exercise of the warrant based on the closing price of the Common Stock. Such a cashless exercise would result in the issuance to SEMATECH of 1,209,631 shares of the Company's Common Stock (assuming a price per share of $44.125). The proceeds from the sale of the warrants were received in October 1994 and were utilized to increase SVGL's manufacturing capacity to satisfy anticipated demand for the current and future versions of the Micrascan product. Additionally, over a three-year period, SEMATECH agreed to fund, upon SVGL's completion of certain milestones, approximately $22,000,000 for the future development of Micrascan technology and the increased manufacturing capacity to build the Micrascan product. During the term of the agreement the Company is obligated to fund, from its own resources, not less than 120% of the total amount received from SEMATECH (including the proceeds of the sale of the warrants) up to a maximum of 21 24 $36,000,000. To fulfill the Company's obligations, such amounts must be incurred to further the development of Micrascan technology, to increase manufacturing capability and capacity for Micrascan products and to fund related inventory costs. The Company has historically devoted a significant portion of its personnel and financial resources to research and development programs. For fiscal years 1993, 1994 and the first nine months of 1995, total gross research and development expenditures were approximately $34,000,000, $32,000,000 and $37,000,000, respectively, of which approximately $8,000,000, $1,500,000 and $8,600,000, respectively, was funded primarily by IBM and SEMATECH for Micrascan technologies and offset against research and development expenses. COMPETITION The semiconductor equipment industry is intensely competitive. The Company faces substantial competition both in the United States and other countries in all of its products. The trend toward consolidation in the semiconductor processing equipment industry has made it increasingly important to have the financial resources necessary to compete effectively across a broad range of product offerings, to fund customer service and support on a worldwide basis and to invest in both product and process research and development. Significant competitive factors include product performance, price and reliability, familiarity with particular manufacturers' products, established relationships between suppliers and customers, particulate contamination control and product availability. While the Company believes that outside Japan and the Pacific Rim it competes favorably with respect to most of these factors, it has occasionally been subject to intense price competition with respect to particular orders and has had difficulty establishing new relationships with certain customers who have long-standing relationships with other suppliers. Certain of the Company's existing and potential competitors have substantially greater name recognition, financial, engineering, manufacturing and marketing resources and customer service and support capabilities than the Company. Due to the Company's position in the photolithography market, an announcement of a new product by any of these large competitors may cause customers to delay purchases until the new product is introduced. The Company's competitors can be expected to continue to improve the design and performance of their current products and processes and to introduce new products and processes with improved price/performance characteristics. There can be no assurance that the Company will be able to compete effectively in the future. The Company faces substantial foreign and domestic competition, including that from Tokyo Electron, Ltd. ("TEL") and DaiNippon Screen Mfg. Co., Ltd. in photoresist processing equipment and TEL and Kokusai Electric Co., Ltd. in oxidation/diffusion and LPCVD equipment. SVGL competes with other suppliers of photolithography exposure equipment, including manufacturers of steppers and projection aligners. SVGL's Micralign products are generally not competitive with steppers for fabrication of semiconductor devices with line widths smaller than 1.25 micron. In marketing Micrascan systems, SVGL faces competition from suppliers employing other technologies, principally I-Line steppers, including Nikon Corp., Canon and ASM Lithography. Certain stepper manufacturers have utilized techniques, such as the use of off-axis illumination and phase shift mask technology, to extend the capabilities of steppers beyond their previously estimated limits. Although the Company believes that its step and scan system will compete favorably with steppers employing these techniques, the status of the development of such techniques is uncertain and the Company expects the competition from such stepper manufacturers to be intense. Additionally, both Nikon and Canon have announced photolithography products using step and scan technology and a Deep UV light source and Nikon has indicated that it expects to deliver initial 0.25 micron production units in mid-1996. Nikon, and to a lesser extent Canon, have long-established relationships as suppliers of photolithography equipment to most of the semiconductor manufacturers. While the Company has supplied Track and Thermco equipment to many of these customers, it has not previously sold Micrascan photolithography equipment to them. In addition, the Company believes that other potential competitors, including ASM Lithography, are developing step and scan technologies. 22 25 UNDERWRITERS Under the terms and subject to the conditions contained in an Underwriting Agreement dated the date hereof, the U.S. Underwriters named below have severally agreed to purchase, and the Company has agreed to sell to them, and the International Underwriters named below have severally agreed to purchase and the Company has agreed to sell to them, the respective number of shares of Common Stock set forth opposite their respective names below:
NUMBER NAME OF SHARES ---------------------------------------------------------------------------------- --------- U.S. Underwriters: Morgan Stanley & Co. Incorporated............................................... Prudential Securities Incorporated.............................................. Cowen & Company................................................................. --------- Subtotal..................................................................... 2,800,000 --------- International Underwriters: Morgan Stanley & Co. International Limited...................................... Prudential-Bache Securities (U.K.) Inc.......................................... Cowen & Company................................................................. --------- Subtotal..................................................................... 700,000 --------- Total................................................................... 3,500,000 ========
The U.S. Underwriters and International Underwriters are collectively referred to as the "Underwriters." The Underwriting Agreement provides that the obligations of the several Underwriters to pay for and accept delivery of the shares of Common Stock offered hereby are subject to the approval of certain legal matters by their counsel and to certain other conditions, including the conditions that no stop order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose are pending before or threatened by the Securities and Exchange Commission and that there has been no material adverse change or any development involving a prospective material adverse change in the business, financial condition or results of operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Registration Statement. The Underwriters are obligated to take and pay for all of the shares of Common Stock offered hereby (other than those covered by the over-allotment option described below) if any such shares are taken. Pursuant to the Agreement Between U.S. and International Underwriters, each U.S. Underwriter has represented and agreed that, with certain exceptions set forth below, (a) it is not purchasing any U.S. Shares (as defined below) for the account of anyone other than a United States or Canadian Person (as defined below) and (b) it has not offered or sold, and will not offer or sell, directly or indirectly, any U.S. Shares or distribute this Prospectus outside the United States or Canada or to anyone other than a United States or Canadian Person. Pursuant to the Agreement Between U.S. and International Underwriters, each International Underwriter has represented and agreed that, with certain exceptions set forth below, (a) it is not purchasing any International Shares (as defined below) for the account of any United States or Canadian Person and (b) it has not offered or sold, and will not offer or sell, directly or indirectly, any International Shares or distribute this Prospectus within the United States or Canada or to any United States or Canadian Person. The foregoing limitations do not apply to stabilization transactions or to certain other transactions specified in the Agreement Between U.S. and International Underwriters. With respect to Cowen & Company, the foregoing representations or agreements (i) made by it in its capacity as a U.S. Underwriter shall apply only to shares of Common Stock purchased by it in its capacity as a U.S. Underwriter, (ii) made by it in its capacity as an International Underwriter shall apply only to shares of Common Stock purchased by it in its capacity as an International Underwriter and (iii) shall not restrict its ability to distribute this Prospectus to any person. As used herein, "United States or Canadian Person" means any national or resident of the United States or Canada or any corporation, pension, profit-sharing or other trust or other entity organized under the laws of the United States or Canada or of any political subdivision 23 26 thereof (other than a branch located outside of the United States and Canada of any United States or Canadian Person) and includes any United States or Canadian branch of a person who is not otherwise a United States or Canadian Person, and "United States" means the United States of America, its territories, its possessions and all areas subject to its jurisdiction. All shares of Common Stock to be offered by the U.S. Underwriters and International Underwriters under the Underwriting Agreement are referred to herein as the "U.S. Shares" and the "International Shares," respectively. Pursuant to the Agreement Between U.S. and International Underwriters, sales may be made between the U.S. Underwriters and the International Underwriters of any number of shares of Common Stock to be purchased pursuant to the Underwriting Agreement as may be mutually agreed. The per share price and currency settlement of any shares of Common Stock so sold shall be the public offering price set forth on the cover page hereof, in United States dollars, less an amount not greater than the per share amount of the concession to dealers set forth below. Pursuant to the Agreement Between U.S. and International Underwriters, each U.S. Underwriter has represented that it has not offered or sold, and has agreed not to offer or sell, any shares of Common Stock, directly or indirectly, in Canada in contravention of the securities laws of Canada or any province or territory thereof and has represented that any offer of such shares in Canada will be made only pursuant to an exemption from the requirement to file a prospectus in the province or territory of Canada in which such offer is made. Each U.S. Underwriter has further agreed to send to any dealer who purchases from it any shares of Common Stock a notice stating in substance that, by purchasing such shares, such dealer represents and agrees that it has not offered or sold, and will not offer or sell, directly or indirectly, any of such shares in Canada in contravention of the securities laws of Canada or any province or territory thereof and that any offer of shares of Common Stock in Canada will be made only pursuant to an exemption from the requirement to file a prospectus in the province or territory of Canada in which such offer is made, and that such dealer will deliver to any other dealer to whom it sells any of such shares a notice to the foregoing effect. Pursuant to the Agreement Between U.S. and International Underwriters, each International Underwriter has represented that (i) it has not offered or sold and will not offer or sell any shares of Common Stock to persons in the United Kingdom except to persons whose ordinary activities involve them in acquiring, holding, managing or disposing of investments (as principal or agent) for the purposes of their businesses or otherwise in circumstances which have not resulted and will not result in an offer to the public in the United Kingdom within the meaning of the Public Offers of Securities Regulations 1995 (the "Regulations"), (ii) it has complied and will comply with all applicable provisions of the Financial Services Act 1986 and the Regulations with respect to anything done by it in relation to such shares in, from or otherwise involving the United Kingdom, and (iii) it has only issued or passed on and will only issue or pass on to any person in the United Kingdom any document received by it in connection with the issue of such shares of Common Stock, if that person is of a kind described in Article 11(3) of the Financial Services Act 1986 (Investment Advertisements) (Exemptions) Order 1995, or is a person to whom such document may otherwise lawfully be issued or passed on. Pursuant to the Agreement Between U.S. and International Underwriters, each International Underwriter has represented and agreed that it has not offered or sold, and will not offer or sell, directly or indirectly, in Japan or to or for the account of any resident thereof, any shares of Common Stock acquired in connection with this offering, except for offers or sales to Japanese International Underwriters or dealers and except pursuant to any exemption from the registration requirements of the Securities and Exchange Law of Japan. Each International Underwriter has further agreed to send to any dealer who purchases from it any of such shares of Common Stock a notice stating in substance that such dealer may not offer or sell any of such shares, directly or indirectly, in Japan or to or for the account of any resident thereof, except pursuant to any exemption from the registration requirements of the Securities and Exchange Law of Japan, and that such dealer will send to any other dealer to whom it sells any of such shares a notice to the foregoing effect. The Underwriters initially propose to offer part of the shares directly to the public at the public offering price set forth on the cover page hereof and part to certain dealers at a price that represents a concession not in 24 27 excess of $ per share under the public offering price. Any Underwriter may allow, and such dealers may reallow, a concession not in excess of $ per share to other Underwriters or to certain other dealers. The Company has granted to the U.S. Underwriters an option, exercisable for 30 days from the date of this Prospectus, to purchase up to an additional 525,000 shares of Common Stock at the public offering price set forth on the cover page hereof, less underwriting discounts and commissions. The U.S. Underwriters may exercise such option solely for the purpose of covering over-allotments, if any, made in connection with this offering. To the extent such option is exercised, each U.S. Underwriter will become obligated, subject to certain conditions, to purchase approximately the same percentage of such additional shares as the number set forth next to such U.S. Underwriter's name in the preceding table bears to the total number of U.S. Shares offered hereby. The Company and the Underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the "Securities Act"). See "Risk Factors -- Shares Eligible for Future Sale" for a description of certain arrangements pursuant to which all officers and directors of the Company have agreed that they will not, without the prior written consent of Morgan Stanley & Co. Incorporated, sell or otherwise dispose of Common Stock of the Company for 90 days after the date of this Prospectus. In addition, the Investors and SEMATECH have agreed that they will not, without the prior written consent of Morgan Stanley & Co. Incorporated, sell or otherwise dispose of Common Stock of the Company until February 19, 1996. The Company has agreed in the Underwriting Agreement that it will not, without the prior written consent of Morgan Stanley & Co. Incorporated, offer, sell, contract to sell or otherwise dispose of any shares of Common Stock or any securities convertible into or exchangeable for Common Stock for a period of 90 days after the date of this Prospectus, except pursuant to existing employee benefit plans and existing warrants. In connection with this offering, certain Underwriters and selling group members (if any) or their respective affiliates who are qualified registered market makers on The Nasdaq National Market, may engage in passive market making transactions in the Common Stock on The Nasdaq National Market in accordance with Rule 10b-6A under the Exchange Act during the two business day period before commencement of offers or sales of the Common Stock. The passive market making transactions must comply with applicable volume and price limits and be identified as such. In general, a passive market maker may display its bid at a price not in excess of the highest independent bid for the security; if all independent bids are lowered below the passive market maker's bid, however, such bid must then be lowered when certain purchase limits are exceeded. LEGAL MATTERS Wilson Sonsini Goodrich & Rosati, P.C., Palo Alto, California, counsel to the Company, will render an opinion that the shares offered hereby will be duly authorized, validly issued, fully paid and nonassessable. Larry W. Sonsini, a member of such firm, is a director of and Secretary of the Company and holds options to purchase 19,500 shares of Common Stock. Certain legal matters in connection with the Offering, will be passed upon for the Underwriters by Morrison & Foerster, Palo Alto, California. EXPERTS The consolidated financial statements and related financial statement schedule of the Company as of September 30, 1993 and 1994 and for each of the three years in the period ended September 30, 1994 incorporated in this Prospectus by reference from the Company's Annual Report on Form 10-K for the year ended September 30, 1994 have been audited by Deloitte & Touche LLP, independent auditors, as stated in their reports which are incorporated herein by reference, and have been so incorporated in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing. 25 28 AVAILABLE INFORMATION The Company has filed with the Commission a Registration Statement on Form S-3 (referred to herein, together with all amendments and exhibits, as the "Registration Statement") under the Securities Act, with respect to the securities offered by this Prospectus. This Prospectus does not contain all of the information set forth in the Registration Statement, certain parts of which have been omitted in accordance with the rules and regulations of the Commission. For further information with respect to the Company and the securities offered hereby, reference is made to the Registration Statement. Statements made in this Prospectus as to the contents of any contract or other document referred to herein are not necessarily complete and, in each instance in which a copy of such contract is filed as an exhibit to the Registration Statement, reference is made to such copy and each such statement shall be deemed qualified in all respects by such reference. Copies of the Registration Statement may be inspected, without charge, at the offices of the Commission, or obtained at prescribed rates from the Public Reference Section of the Commission at the address set forth below. The Company is subject to the informational requirements of the Exchange Act, and in accordance therewith files reports, proxy statements and other information with the Commission. Such reports, proxy statements and other information filed by the Company can be inspected and copied at the public reference facilities of the Commission located at 450 Fifth Street, N.W., Washington, D.C. 20549 and at the Commission's regional offices at Seven World Trade Center, New York, New York 10048 and Northwestern Atrium Center, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661. Copies of such material also can be obtained from the Public Reference Section of the Commission at 450 Fifth Street, N.W., Washington, D.C. 20549, at prescribed rates. The Company's Common Stock is quoted for trading on The Nasdaq National Market and reports, proxy statements and other information concerning the Company may be inspected at the offices of the National Association of Securities Dealers, Inc., 9513 Key West Avenue, Rockville, Maryland 20850. 26 29 INFORMATION CONTAINED HEREIN IS SUBJECT TO COMPLETION OR AMENDMENT. A REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE REGISTRATION STATEMENT BECOMES EFFECTIVE. THIS PROSPECTUS SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH STATE. [ALTERNATE PAGE] PROSPECTUS (Subject to Completion) Issued September , 1995 3,500,000 Shares (LOGO) COMMON STOCK ------------------------ OF THE 3,500,000 SHARES OF COMMON STOCK BEING OFFERED, 700,000 SHARES ARE BEING OFFERED INITIALLY OUTSIDE OF THE UNITED STATES AND CANADA BY THE INTERNATIONAL UNDERWRITERS AND 2,800,000 SHARES ARE BEING OFFERED INITIALLY IN THE UNITED STATES AND CANADA BY THE U.S. UNDERWRITERS. SEE "UNDERWRITERS." ALL OF THE 3,500,000 SHARES OF COMMON STOCK OFFERED HEREBY ARE BEING SOLD BY THE COMPANY. THE COMPANY'S COMMON STOCK IS TRADED IN THE OVER-THE-COUNTER MARKET UNDER THE NASDAQ NATIONAL MARKET SYMBOL "SVGI." THE LAST SALE PRICE FOR THE COMMON STOCK ON SEPTEMBER 7, 1995, AS REPORTED ON THE NASDAQ NATIONAL MARKET, WAS $44 1/8 PER SHARE. SEE "PRICE RANGE OF COMMON STOCK." ------------------------ THIS OFFERING INVOLVES A HIGH DEGREE OF RISK. SEE "RISK FACTORS" COMMENCING ON PAGE 6. ------------------------ THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. ------------------------ PRICE $ A SHARE ------------------------
UNDERWRITING PRICE TO DISCOUNTS AND PROCEEDS TO PUBLIC COMMISSIONS(1) COMPANY(2) --------------------- --------------------- --------------------- Per Share....................... $ $ $ Total(3)........................ $ $ $
------------ (1) The Company has agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended. See "Underwriters." (2) Before deducting expenses payable by the Company estimated at $350,000. (3) The Company has granted to the U.S. Underwriters an option, exercisable within 30 days of the date hereof, to purchase up to 525,000 additional Shares at the price to public less underwriting discounts and commissions for the purpose of covering over-allotments, if any. If the U.S. Underwriters exercise such option in full, the total price to public, underwriting discounts and commissions and proceeds to Company will be $ , $ , and $ , respectively. See "Underwriters." ------------------------ The Shares are offered subject to prior sale, when, as and if accepted by the Underwriters named herein and subject to approval of certain legal matters by Morrison & Foerster, counsel for the Underwriters. It is expected that delivery of the Shares will be made on or about , 1995 at the offices of Morgan Stanley & Co. Incorporated, New York, N.Y., against payment therefor in New York funds. ------------------------ MORGAN STANLEY & CO. International PRUDENTIAL-BACHE SECURITIES COWEN & COMPANY , 1995 30 [ALTERNATE PAGE] NO PERSON IS AUTHORIZED IN CONNECTION WITH ANY OFFERING MADE HEREBY TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATION NOT CONTAINED OR INCORPORATED BY REFERENCE IN THIS PROSPECTUS, AND ANY INFORMATION OR REPRESENTATION NOT CONTAINED OR INCORPORATED HEREIN MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY OR ANY UNDERWRITER. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY BY ANY PERSON IN ANY JURISDICTION IN WHICH IT IS UNLAWFUL FOR SUCH PERSON TO MAKE SUCH AN OFFERING OR SOLICITATION. NEITHER THE DELIVERY OF THIS PROSPECTUS AT ANY TIME NOR ANY SALE MADE HEREUNDER SHALL UNDER ANY CIRCUMSTANCE IMPLY THAT THE INFORMATION HEREIN IS CORRECT AS OF ANY DATE SUBSEQUENT TO THE DATE HEREOF. ------------------------ TABLE OF CONTENTS
PAGE ---- Incorporation of Certain Documents by Reference............................................ 2 Prospectus Summary......................................................................... 3 The Company................................................................................ 4 Risk Factors............................................................................... 6 Use of Proceeds............................................................................ 11 Price Range of Common Stock................................................................ 12 Dividend Policy............................................................................ 12 Capitalization............................................................................. 13 Selected Consolidated Financial Data....................................................... 14 Business................................................................................... 16 Underwriters............................................................................... 23 Legal Matters.............................................................................. 25 Experts.................................................................................... 25 Available Information...................................................................... 26
------------------------ INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE The following documents heretofore filed by the Company with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act") are incorporated herein by reference: (1) the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 1994; (2) the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 1994; (3) the Company's Current Report on Form 8-K filed on March 2, 1995; (4) the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 1995; (5) the Company's Quarterly report on Form 10-Q for the quarter ended June 30, 1995; and (6) the Company's Registration Statement on Form 8-A filed with the Commission on November 23, 1983. All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this Prospectus and prior to the termination of the offering of the Common Stock hereunder shall be deemed to be incorporated by reference herein and to be a part hereof from the date of the filing of such reports and documents. The Company will provide a copy of any or all of such documents (exclusive of exhibits unless such exhibits are specifically incorporated by reference herein), without charge, to each person to whom this Prospectus is delivered, upon written or oral request to the Chief Financial Officer at the corporate headquarters of the Company, 2240 Ringwood Avenue, San Jose, California 95131 (telephone 408-434-0500). Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Prospectus to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Prospectus. ------------------------ IN CONNECTION WITH THIS OFFERING, THE UNDERWRITERS MAY OVER-ALLOT OR EFFECT TRANSACTIONS WHICH STABILIZE OR MAINTAIN THE MARKET PRICE OF THE COMMON STOCK OFFERED HEREBY AT A LEVEL ABOVE THAT WHICH MIGHT OTHERWISE PREVAIL IN THE OPEN MARKET. SUCH TRANSACTIONS MAY BE EFFECTED ON THE NASDAQ NATIONAL MARKET, IN THE OVER-THE-COUNTER MARKET OR OTHERWISE. SUCH STABILIZING, IF COMMENCED, MAY BE DISCONTINUED AT ANY TIME. THE INTERNATIONAL SHARES MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR CANADA OR TO ANY PERSON WHO IS A UNITED STATES OR CANADIAN PERSON, AS PART OF THE DISTRIBUTION OF THE INTERNATIONAL SHARES. ALL APPLICABLE PROVISIONS OF THE FINANCIAL SERVICES ACT 1986, PUBLIC OFFERS OF SECURITIES REGULATIONS 1995 AND COMPANIES ACT 1985 MUST BE COMPLIED WITH. FOR A DESCRIPTION OF THESE AND OTHER RESTRICTIONS ON THE OFFERING AND SALE OF SUCH SHARES. SEE "UNDERWRITERS." IN CONNECTION WITH THIS OFFERING, CERTAIN UNDERWRITERS AND SELLING GROUP MEMBERS (IF ANY) OR THEIR RESPECTIVE AFFILIATES MAY ENGAGE IN PASSIVE MARKET MAKING TRANSACTIONS IN THE COMMON STOCK ON THE NASDAQ NATIONAL MARKET IN ACCORDANCE WITH RULE 10B-6A UNDER THE SECURITIES EXCHANGE ACT OF 1934. SEE "UNDERWRITERS." 2 31 [LOGO] 32 PART II INFORMATION NOT REQUIRED IN PROSPECTUS ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION SEC Registration Fee.............................................. $ 61,850 NASD Filing Fee................................................... 18,437 The Nasdaq National Market Listing Fee............................ 17,500 Blue Sky Fees and Expenses........................................ 12,000 Legal Fees and Expenses........................................... 100,000 Accounting Fees and Expenses...................................... 60,000 Printing and Engraving Expenses................................... 50,000 Transfer Agent and Registrar Fees................................. 2,500 Miscellaneous..................................................... 27,713 -------- Total................................................... $350,000 ========
All of the amounts shown other than the SEC, NASD and Nasdaq fees are estimated. ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS The Delaware General Corporation Law authorizes a court to award, or a corporation's Board of Directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities (including reimbursement for expenses incurred) arising out of the Securities Act of 1933, as amended (the "Securities Act"). Article VI of the Company's Bylaws provides for indemnification of its directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law. The Underwriting Agreement (Exhibit 1.1) provides for the indemnification by the Underwriters, of the Registrant and its officers and directors, and by the Registrant of the Underwriters, for certain liabilities arising under the Securities Act, or otherwise. ITEM 16. EXHIBITS
EXHIBIT NUMBER ------ 1.1 Form of Underwriting Agreement 5.1 Opinion of Wilson Sonsini Goodrich & Rosati, P.C. as to the legality of the shares of common stock being registered. 23.1 Consent of Deloitte & Touche LLP (see page II-4) 23.2 Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1) 24.1 Power of Attorney (see page II-3)
ITEM 17. UNDERTAKINGS The undersigned Registrant hereby undertakes: 1. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the Delaware Corporation Law, the Underwriting Agreement or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person for liabilities arising under the Securities Act in connection with the securities being registered hereunder, the Registrant will, unless in the opinion of its counsel the question has been settled by controlling precedent, II-1 33 submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. 2. For purposes of determining any liability under the Securities Act, the information omitted from the form of Prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of Prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective. 3. For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of Prospectus shall be deemed to be a new Registration Statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. 4. For the purpose of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. II-2 34 SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the Registrant, Silicon Valley Group, Inc., a corporation organized and existing under the law of the State of Delaware, certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Jose, State of California, on the 8th day of September, 1995. SILICON VALLEY GROUP, INC. By: /s/ RUSSELL G. WEINSTOCK ------------------------------------ Russell G. Weinstock Vice President, Finance and Chief Financial Officer POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Russell G. Weinstock his attorney-in-fact, with the power of substitution, for him in any and all capacities, to sign any and all amendments to this Registration Statement and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorney-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.
SIGNATURE TITLE DATE ------------------------------------------ ------------------------------ ------------------- /s/ PAPKEN S. DER TOROSSIAN Chairman of the Board and September 8, 1995 ------------------------------------------ Chief Executive Officer (Papken S. Der Torossian) /s/ RUSSELL G. WEINSTOCK Vice President, Finance and September 8, 1995 ------------------------------------------ Chief Financial Officer (Russell G. Weinstock) /s/ WILLIAM A. HIGHTOWER Director September 8, 1995 ------------------------------------------ (William A. Hightower) /s/ WILLIAM L. MARTIN Director September 8, 1995 ------------------------------------------ (William L. Martin) /s/ LARRY W. SONSINI Director September 8, 1995 ------------------------------------------ (Larry W. Sonsini) /s/ NAM P. SUH Director September 8, 1995 ------------------------------------------ (Nam P. Suh)
II-3 35 EXHIBIT 23.1 INDEPENDENT AUDITORS' CONSENT We consent to the incorporation by reference in this Registration Statement of Silicon Valley Group, Inc. on Form S-3 of our reports dated October 22, 1994 included and incorporated by reference in the Annual Report on Form 10-K of Silicon Valley Group, Inc. for the year ended September 30, 1994. We also consent to the reference to us under the headings "Selected Consolidated Financial Information" and "Experts" in such Prospectus. DELOITTE & TOUCHE LLP San Jose, California September 7, 1995 II-4 36 INDEX TO EXHIBITS
SEQUENTIALLY EXHIBIT NUMBERED NUMBER EXHIBITS PAGE ------- ---------------------------------------------------------------------------- 1.1 Form of Underwriting Agreement 5.1 Opinion of Wilson Sonsini Goodrich & Rosati, P.C. as to the legality of the shares of common stock being registered. 23.1 Consent of Deloitte & Touche LLP (see page II-4) 23.2 Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1) 24.1 Power of Attorney (see page II-3)
EX-1.1 2 UNDERWRITING AGREEMENT 1 Exhibit 1.1 3,500,000 Shares SILICON VALLEY GROUP, INC. Common Stock ($0.01 per share par value) UNDERWRITING AGREEMENT ____________________, 1995 2 ___________________, 1995 Morgan Stanley & Co. Incorporated Prudential Securities Incorporated Cowen & Company the U.S. Underwriters named in Schedule I herein c/o Morgan Stanley & Co. Incorporated 1251 Avenue of the Americas New York, New York 10020 Morgan Stanley & Co. International Limited Prudential-Bache Securities (UK) Inc. Cowen & Company the International Underwriters named in Schedule II herein c/o Morgan Stanley & Co. International Limited 25 Cabot Square Canary Wharf London E14 4QA England Dear Sirs: Silicon Valley Group, Inc., a Delaware corporation (the "Company"), proposes to issue and sell to the several Underwriters (as defined below) 3,500,000 shares of its Common Stock ($0.01 per share par value) (the "Firm Shares"). It is understood that, subject to the conditions hereinafter stated, 2,800,000 Firm Shares (the "U.S. Firm Shares") will be issued and sold to the several U.S. Underwriters named in Schedule I hereto (the "U.S. Underwriters") in connection with the offering and sale of such U.S. Firm Shares in the United States and Canada to United States and Canadian Persons (as such terms are defined in the Agreement Between U.S. and International Underwriters of even date herewith), and 700,000 Firm Shares (the "International Shares") will be issued and sold to the several International Underwriters named in Schedule II hereto -1- 3 (the "International Underwriters") in connection with the offering and sale of such International Shares outside the United States and Canada to persons other than United States and Canadian Persons. The U.S. Underwriters and the International Underwriters are hereinafter collectively referred to as the Underwriters. The Company also proposes to issue and sell to the several U.S. Underwriters not more than an additional 525,000 shares of its Common Stock ($0.01 per share par value) (the "Additional Shares") if and to the extent that the U.S. Underwriters shall have determined to exercise the right to purchase such shares of common stock granted to them in Article II hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the Shares. The shares of Common Stock ($0.01 per share par value) of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the Common Stock. The Company has filed with the Securities and Exchange Commission (the "Commission") a registration statement relating to the Shares. The registration statement contains two prospectuses to be used in connection with the offering and sales of the Shares: the U.S. prospectus, to be used in connection with the offering and sale of Shares in the United States and Canada to United States and Canadian Persons, and the international prospectus, to be used in connection with the offering and sale of Shares outside the United States and Canada to persons other than United States and Canadian Persons. The international prospectus is identical to the U.S. prospectus except for the outside and inside front cover pages. The registration statement as amended at the time it becomes effective, including the information (if any) deemed to be part of the registration statement at the time of effectiveness pursuant to Rule 430A under the Securities Act of 1933, as amended (the "Securities Act"), is hereinafter referred to as the Registration Statement; the U.S. prospectus and the international prospectus in the respective forms first used to confirm sales of Shares are hereinafter collectively referred to as the Prospectus (including, in the case of all references to the Registration Statement and the Prospectus, documents incorporated therein by reference). If the Company files a registration statement to register a portion of the Shares and relies on Rule 462(b) for such registration statement to become effective upon filing with the Commission (the "Rule 462 Registration Statement"), then any reference to the "Registration Statement" shall be deemed to include the Rule 462 Registration as amended from time to time. -2- 4 I. The Company represents and warrants to each of the Underwriters that: (a) The Registration Statement has become effective; no stop order suspending the effectiveness of the Registration Statement is in effect, and no proceedings for such purpose are pending before or threatened by the Commission. (b) (i) The Company has filed in a timely manner each document or report required to be filed by it pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules and regulations thereunder, (ii) each such document complied, or will comply when so filed, in all material respects with the Exchange Act and the applicable rules and regulations thereunder, (iii) each part of the Registration Statement, when such part became effective, did not contain and each such part, as amended or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (iv) the Registration Statement and the Prospectus comply and, as amended or supplemented, if applicable, will comply in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder and (v) the Prospectus does not contain and, as amended or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this Paragraph 1(b) do not apply to statements or omissions in the Registration Statement or the Prospectus based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through you expressly for use therein. (c) The Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the Company and its subsidiaries, taken as a whole. (d) Each subsidiary of the Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its -3- 5 ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the Company and its subsidiaries, taken as a whole. (e) The authorized capital stock of the Company conforms as to legal matters to the description thereof contained in the Prospectus. (f) The shares of Common Stock outstanding prior to the issuance of the Shares to be sold by the Company have been duly authorized and are validly issued, fully paid and non-assessable. (g) The Shares to be sold by the Company have been duly authorized and, when issued and delivered in accordance with the terms of this Agreement, will be validly issued, fully paid and non-assessable, and the issuance of such Shares will not be subject to any preemptive or similar rights. (h) This Agreement has been duly authorized, executed and delivered by the Company. (i) The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not contravene any provision of applicable law or the certificate of incorporation or by-laws of the Company or any agreement or other instrument binding upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, or any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, and no consent, approval, authorization or order of or qualification with any governmental body or agency is required for the performance by the Company of its obligations under this Agreement, except such as may be required by the Securities Act or the securities or Blue Sky laws of the various states in connection with the offer and sale of the Shares. (j) There has not occurred any material adverse change, or any development involving a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Prospectus. (k) There are no legal or governmental proceedings, pending or, to the best of the Company's knowledge, threatened, to which the Company or any of its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject that are required to be described in the Registration Statement or the Prospectus and are not so described or any statutes, regulations, contracts or other documents that are required to be described in the Registration Statement or the Prospectus or to be -4- 6 filed as exhibits to the Registration Statement that are not described or filed as required. (l) Each of the Company and its subsidiaries has all necessary consents, authorizations, approvals, orders, certificates and permits of and from, and has made all declarations and filings with, all federal, state, local and other governmental authorities, all self-regulatory organizations and all courts and other tribunals, to own, lease, license and use its properties and assets and to conduct its business in the manner described in the Prospectus, except to the extent that the failure to obtain or file would not have a material adverse effect on the Company and its subsidiaries, taken as a whole. (m) Each preliminary prospectus filed as part of the registration statement as originally filed or as part of any amendment thereto, or filed pursuant to Rule 424 or Rule 462 under the Securities Act, complied when so filed in all material respects with the Securities Act and the rules and regulations of the Commission thereunder. (n) The Company is not an "investment company" or an entity "controlled" by an "investment company" as such terms are defined in the Investment Company Act of 1940, as amended. (o) The Company and its subsidiaries are (i) in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants ("Environmental Laws"), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole. (p) The Company has reasonably concluded that costs and liabilities associated with Environmental Laws would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole. (q) The Company has complied with all provisions of Section 517.075, Florida Statutes (Chapter 92-198, Laws of Florida). -5- 7 II. The Company hereby agrees to sell to the several Underwriters, and each Underwriter, upon the basis of the representations and warranties herein contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to purchase from the Company at $______ a share (the purchase price) the respective number of Firm Shares (subject to such adjustments to eliminate fractional shares as you may determine) that bears the same proportion to the number of Firm Shares to be sold by the Company as the aggregate number of Firm Shares set forth in Schedules I and II hereto opposite the name of such Underwriter bears to the total number of Firm Shares. On the basis of the representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees to sell to the U.S. Underwriters the Additional Shares, and the U.S. Underwriters shall have a one-time right to purchase, severally and not jointly, up to 525,000 Additional Shares at the purchase price. Additional Shares may be purchased as provided in Article IV hereof solely for the purpose of covering over-allotments made in connection with the offering of the Firm Shares. If any Additional Shares are to be purchased, each U.S. Underwriter agrees, severally and not jointly, to purchase the number of Additional Shares (subject to such adjustments to eliminate fractional shares as you may determine) that bears the same proportion to the total number of Additional Shares to be purchased as the number of U.S. Firm Shares set forth in Schedule I hereto opposite the name of such U.S. Underwriter bears to the total number of U.S. Firm Shares. The Company hereby agrees that, without the prior written consent of Morgan Stanley & Co. Incorporated, it will not offer, sell, contract to sell or otherwise dispose of any shares of Common Stock of the Company or any securities convertible into or exercisable or exchangeable for such Common Stock for a period of ninety (90) days after the date of the public offering of the Shares, other than (i) the Shares to be sold hereunder and (ii) any shares of such Common Stock which may be sold by the Company upon the exercise of an option or warrant or the conversion of a security in any such case only to the extent such security was outstanding on the date hereof. III. The Company is advised by you that the Underwriters propose to make a public offering of their respective portions of the Shares as soon after the Registration Statement and this Agreement have become effective as in your judgment is advisable. The Company is further advised by you that the Shares are to be offered to the public at $______ a share (the public offering price) and to certain dealers selected by you at a price that represents a concession not in excess of $____ a share under the public offering price, and that any -6- 8 Underwriter may allow, and such dealers may reallow, a concession, not in excess of $____ a share, to any Underwriter or to certain other dealers. Each U.S. Underwriter hereby makes to and with the Company the representations and agreements of such U.S. Underwriter contained in the fifth and sixth paragraphs of Article III of the Agreement Between U.S. and International Underwriters of even date herewith. Each International Underwriter hereby makes to and with the Sellers the representations and agreements of such International Underwriter contained in the seventh, eighth, ninth and tenth paragraphs of Article III of such Agreement. Copies of such fifth, sixth, seventh, eighth, ninth and tenth paragraphs of Article III of the Agreement Between U.S. and International Underwriters are attached hereto as Schedule III. IV. Payment for the Firm Shares to be sold by the Company shall be made by certified or official bank check payable to the order of the Company in New York Clearing House funds at the office of Wilson, Sonsini, Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304-1050, at 7:00 A.M., local time, on October ___, 1995, or at such other time on the same or such other date, not later than October ___, 1995, as shall be designated in writing by you. The time and date of each such payment are hereinafter referred to as the Closing Date. Payment for any Additional Shares shall be made by certified or official bank check or checks payable to the order of the Company in New York Clearing House funds at the office of Wilson, Sonsini, Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304-1050, at 7:00 A.M., local time, on such date (which may be the same as the Closing Date but shall in no event be earlier than the Closing Date nor later than ten (10) business days after the giving of the notice hereinafter referred to) as shall be designated in a written notice from you to the Company of your determination, on behalf of the Underwriters, to purchase a number, specified in said notice, of Additional Shares, or on such other date, in any event not later than November ____, 1995, as shall be designated in writing by you. The time and date of such payment are hereinafter referred to as the Option Closing Date. The notice of the determination to exercise the option to purchase Additional Shares and of the Option Closing Date may be given at any time within thirty (30) days after the date of this Agreement. Certificates for the Firm Shares and Additional Shares shall be in definitive form and registered in such names and in such denominations as you shall request in writing not later than two (2) full business days prior to the Closing Date or the Option Closing Date, as the case may be. The certificates evidencing the Firm Shares and Additional Shares shall be delivered to you on the Closing Date or the Option Closing Date, as the case may be, for the respective accounts of the several Underwriters, with any transfer taxes payable in -7- 9 connection with the transfer of the Shares to the Underwriters duly paid, against payment of the purchase price therefor. V. The obligations of the Company and the several obligations of the Underwriters hereunder are subject to the condition that the Registration Statement shall have become effective not later than the date hereof. The several obligations of the Underwriters hereunder are subject to the following further conditions: (a) Subsequent to the execution and delivery of this Agreement and prior to the Closing Date, there shall not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in the earnings, business or operations, of the Company and its subsidiaries, taken as a whole, from that set forth in the Registration Statement, that, in your judgment, is material and adverse and that makes it, in your judgment, impracticable to market the Shares on the terms and in the manner contemplated in the Prospectus. (b) The Underwriters shall have received on the Closing Date a certificate, dated the Closing Date and signed by an executive officer of the Company, to the effect that the representations and warranties of the Company contained in this Agreement are true and correct as of the Closing Date and that the Company has complied with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date. The officer signing and delivering such certificate may rely upon the best of his knowledge as to proceedings threatened. (c) You shall have received on the Closing Date an opinion of Wilson, Sonsini, Goodrich & Rosati, counsel for the Company, dated the Closing Date, to the effect that: (i) the Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the Company and its subsidiaries, taken as a whole; -8- 10 (ii) each subsidiary of the Company accounting for five percent (5%) or more of the Company's consolidated revenue for the most recent fiscal year ended has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the Company and its subsidiaries taken as a whole; (iii) the authorized capital stock of the Company conforms as to legal matters to the description thereof contained in the Prospectus; (iv) the shares of Common Stock outstanding prior to the issuance of the Shares to be sold by the Company have been duly authorized and are validly issued, fully paid and non-assessable; (v) the Shares to be sold by the Company have been duly authorized and, when issued and delivered in accordance with the terms of this Agreement, will be validly issued, fully paid and non-assessable, and the issuance of such Shares will not be subject to any preemptive or, to the best of such counsel's knowledge, similar rights; (vi) this Agreement has been duly authorized, executed and delivered by the Company; (vii) the execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not contravene any provision of any federal or Delaware law or the certificate of incorporation or by-laws of the Company or, to the best of such counsel's knowledge, any agreement or other instrument binding upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, or, to the best of such counsel's knowledge, any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, and no consent, approval, authorization or order of or qualification with any governmental body or agency is required for the performance by the Company of its obligations under this Agreement, except such as may be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of the Shares by the U.S. Underwriters; -9- 11 (viii) the statements (1) regarding the Company's Common Stock set forth in the Company's Registration Statement on Form 8-A, and (2) in the Registration Statement in Item 15, in each case insofar as such statements constitute summaries of the legal matters, documents or proceedings referred to therein, fairly present the information called for with respect to such legal matters, documents and proceedings and fairly summarize the matters referred to therein in all material respects; (ix) such counsel does not know of any legal or governmental proceeding pending or threatened to which the Company or any of its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject that is required to be described in the Registration Statement or the Prospectus and is not so described or of any statute, regulation, contract or other document that is required to be described in the Registration Statement or the Prospectus or to be filed as an exhibit to the Registration Statement that is not described or filed as required; and (x) such counsel (1) is of the opinion that each document, if any, filed pursuant to the Exchange Act and incorporated by reference in the Registration Statement and the Prospectus (except for financial statements and schedules as to which such counsel need not express any opinion) complied when so filed as to form in all material respects with the Exchange Act, and the applicable rules and regulations of the Commission thereunder, (2) is of the opinion that the Registration Statement and Prospectus (except for financial statements and schedules included therein as to which such counsel need not express any opinion) comply as to form in all material respects with the Securities Act and the rules and regulations of the Commission thereunder, (3) believes that (except for financial statements and schedules as to which such counsel need not express any belief) the Registration Statement and the prospectus included therein at the time the Registration Statement became effective did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading and (4) believes that (except for financial statements and schedules as to which such counsel need not express any belief) the Prospectus does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. (d) You shall have received on the Closing Date an opinion of Morrison & Foerster, counsel for the Underwriters, dated the Closing Date: -10- 12 (i) covering the matters referred to in subparagraphs (v), (vi) and clauses (3) and (4) of (x) of paragraph (c) above; and (ii) to the effect that the statements in the Prospectus under the caption "Underwriters") insofar as such statements constitute summaries of the legal matters, documents or proceedings referred to therein, fairly present the information called for with respect to such legal matters, documents and proceedings and fairly summarize the matters referred to therein in all material respects. With respect to subparagraph (x) of paragraph (c) above, Wilson, Sonsini, Goodrich & Rosati and Morrison & Foerster may make such statement based upon their participation in the preparation of the Registration Statement and Prospectus and any amendments or supplements thereto (other than the documents incorporated by reference) and upon review and discussion of the contents thereof, but are without independent check or verification except as specified. The opinion of Wilson, Sonsini, Goodrich & Rosati described in paragraph (c) above shall be rendered to you at the request of the Company and shall so state therein. (e) You shall have received, on each of the date hereof and the Closing Date, a letter dated the date hereof or the Closing Date, as the case may be, in form and substance satisfactory to you, from Deloitte & Touche LLP, independent public accountants, containing statements and information of the type ordinarily included in accountants' "comfort letters" to underwriters with respect to the financial statements and certain financial information contained in, or incorporated by reference into, the Registration Statement and the Prospectus. (f) The "lock-up" agreements between you and certain stockholders, officers and directors of the Company relating to sales of shares of Common Stock of the Company or any securities convertible into or exercisable or exchangeable for such Common Stock, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date. The several obligations of the U.S. Underwriters to purchase Additional Shares hereunder are subject to the delivery to the U.S. Underwriters on the Option Closing Date of such documents as they may reasonably request with respect to the good standing of the Company, the due authorization and issuance of the Additional Shares, other matters related to the issuance of the Additional Shares and an opinion of counsel in form and substance satisfactory to counsel for the Underwriters. -11- 13 VI. In further consideration of the agreements of the Underwriters herein contained, the Company covenants as follows: (a) To furnish you, without charge, seven (7) signed copies of the Registration Statement (including exhibits thereto and documents incorporated by reference therein) and, during the period mentioned in paragraph (c) below, as many copies of the Prospectus, any documents incorporated by reference therein, and any supplements and amendments thereto or to the Registration Statement as you may reasonably request. The terms "supplement" and "amendment" or "amend" as used in this Agreement shall include all documents subsequently filed by the Company with the Commission pursuant to the Exchange Act, that are deemed to be incorporated by reference in the Prospectus. In the case of the Prospectus, to furnish copies of the Prospectus in New York City, prior to 10:00 a.m., on the business day next succeeding the date of this Agreement, and in London within two (2) business days of the date of this Agreement, in such quantities as you reasonably request. (b) Before amending or supplementing the Registration Statement or the Prospectus, to furnish to you a copy of each such proposed amendment or supplement and to file no such proposed amendment or supplement to which you reasonably object. (c) If, during such period after the first date of the public offering of the Shares as in the opinion of your counsel the Prospectus is required by law to be delivered in connection with sales by an Underwriter or dealer, any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, not misleading, or if, in the opinion of your counsel, it is necessary to amend or supplement the Prospectus to comply with law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses you will furnish to the Company) to which Shares may have been sold by you on behalf of the Underwriters and to any other dealers upon request, either amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with law. (d) To use reasonable efforts to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as you shall reasonably request. -12- 14 (e) To make generally available to the Company's security holders and to you as soon as practicable an earning statement covering the twelve-month period ending December 31, 1996 that satisfies the provisions of Section 11(a) of the Securities Act and the rules and regulations of the Commission thereunder. (f) To pay all expenses incident to the performance of its obligations under this Agreement, including (i) the preparation and filing of the Registration Statement and the Prospectus and all amendments and supplements thereto, (ii) the preparation, issuance and delivery of the Shares, including any transfer taxes payable in connection with the transfer of the Shares to the Underwriters, (iii) the fees and disbursements of the Company's counsel and accountants, (iv) the qualification of the Shares under state securities or Blue Sky laws in accordance with the provisions of paragraph (d) above, including filing fees and the fees and disbursements of counsel for the Underwriters in connection therewith and in connection with the preparation of any Blue Sky or Legal Investment Memoranda, (v) the printing and delivery to the Underwriters, in quantities as hereinabove stated, copies of the Registration Statement and all amendments and exhibits thereto and of each preliminary prospectus and the Prospectus and any amendments or supplements thereto, (vi) the printing and delivery to the Underwriters of copies of any Blue Sky or Legal Investment Memoranda, (vii) the filing fees and expenses, including fees and disbursements of counsel, incurred with respect to any filing and review with the National Association of Securities Dealers, Inc., made in connection with the offering of the Shares, (viii) any expenses incurred by the Company in connection with a "road show" presentation to potential investors and (ix) the listing of the Common Stock on The Nasdaq National Market. VII. The Company agrees to indemnify and hold harmless each Underwriter and each person, if any, who controls any Underwriter within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) caused by any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereof, any preliminary prospectus or the Prospectus (as amended or supplemented if the Company shall have furnished any amendments or supplements thereto), or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue statement or omission based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through you expressly for use therein; provided, however, that the foregoing indemnity agreement with -13- 15 respect to any preliminary prospectus shall not inure to the benefit of any Underwriter from whom the person asserting any such losses, claims, damages or liabilities purchased Shares, or any person controlling such Underwriter, if a copy of the Prospectus (as then amended or supplemented if the Company shall have furnished any amendments or supplements thereto) was not sent or given by or on behalf of such Underwriter to such person, if required by law so to have been delivered, at or prior to the written confirmation of the sale of the Shares to such person, and if the Prospectus (as so amended or supplemented) would have cured the defect giving rise to such loss, claim, damage or liability. Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, the Selling Stockholder, the directors of the Company, the officers of the Company who sign the Registration Statement and each person, if any, who controls the Company or the Selling Stockholder within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) caused by any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereof, any preliminary prospectus or the Prospectus (as amended or supplemented if the Company shall have furnished any amendments or supplements thereto), or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, but only with reference to information relating to such Underwriter furnished to the Company in writing by such Underwriter through you expressly for use in the Registration Statement, any preliminary prospectus, the Prospectus or any amendments or supplements thereto. In case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of which indemnity may be sought pursuant to any of the three preceding paragraphs, such person (the "indemnified party") shall promptly notify the person against whom such indemnity may be sought (the "indemnifying party") in writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel or (ii) the named parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for (a) the fees and expenses of more than one separate firm (in addition to any local counsel) for all Underwriters and all persons, if any, who control any Underwriter within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act, and (b) the fees and expenses of more than one separate firm (in addition -14- 16 to any local counsel) for the Company, its directors, its officers who sign the Registration Statement and each person, if any, who controls the Company within the meaning of either such Section, and that all such fees and expenses shall be reimbursed as they are incurred. In the case of any such separate firm for the Underwriters and such control persons of Underwriters, such firm shall be designated in writing by Morgan Stanley & Co. Incorporated. In the case of any such separate firm for the Company, and such directors, officers and control persons of the Company, such firm shall be designated in writing by the Company. In the case of any such separate firm for the Selling Stockholder and such controlling persons of the Selling Stockholder, such firm shall be designated in writing by the Selling Stockholder. The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding. If the indemnification provided for in the first, second or third paragraph of this Article VII is unavailable to an indemnified party or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the indemnifying party or parties on the one hand and the indemnified party or parties on the other hand from the offering of the Shares or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the indemnifying party or parties on the one hand and of the indemnified party or parties on the other hand in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other hand in connection with the offering of the Shares shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Shares (before deducting expenses) received by the Company and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate public offering price of the Shares. The relative fault of the Company on the one hand and the Underwriters on the other hand shall be determined by reference to, among -15- 17 other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties' relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Underwriters' respective obligations to contribute pursuant to this Article VII are several in proportion to the respective number of Shares they have purchased hereunder, and not joint. The Company and the Underwriters agree that it would not be just or equitable if contribution pursuant to this Article VII were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in the immediately preceding paragraph. The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in the immediately preceding paragraph shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Article VII, no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies provided for in this Article VII are not exclusive and shall not limit any rights or remedies which may otherwise be available to any indemnified party at law or in equity. The indemnity and contribution provisions contained in this Article VII and the representations and warranties of the Company contained in this Agreement shall remain operative and in full force and effect regardless of (i) any termination of this Agreement, (ii) any investigation made by or on behalf of any Underwriter or any person controlling any Underwriter, or the Company, its officers or directors or any person controlling the Company and (iii) acceptance of and payment for any of the Shares. VIII. This Agreement shall be subject to termination by notice given by you to the Company, if (a) after the execution and delivery of this Agreement and prior to the Closing Date (i) trading generally shall have been suspended or materially limited on or by, as the case may be, any of the New York Stock Exchange, the American Stock Exchange, the National Association of Securities Dealers, Inc., the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade, (ii) trading of any securities of the -16- 18 Company shall have been suspended on any exchange or in any over-the-counter market, (iii) a general moratorium on commercial banking activities in New York shall have been declared by either Federal or New York State authorities, or (iv) there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis that, in your judgment, is material and adverse and (b) in the case of any of the events specified in clauses (a)(i) through (iv), such event singly or together with any other such event makes it, in your judgment, impracticable to market the Shares on the terms and in the manner contemplated in the Prospectus. IX. This Agreement shall become effective upon the later of (x) execution and delivery hereof by the parties hereto and (y) release of notification of the effectiveness of the Registration Statement by the Commission. If, on the Closing Date or the Option Closing Date, as the case may be, any one or more of the Underwriters shall fail or refuse to purchase Shares that it or they have agreed to purchase hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase is not more than one-tenth of the aggregate number of the Shares to be purchased on such date, the other Underwriters shall be obligated severally in the proportions that the number of Firm Shares set forth opposite their respective names in Schedules I and II bears to the aggregate number of Firm Shares set forth opposite the names of all such non-defaulting Underwriters, or in such other proportions as you may specify, to purchase the Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date; provided that in no event shall the number of Shares that any Underwriter has agreed to purchase pursuant to Article II be increased pursuant to this Article IX by an amount in excess of one-ninth of such number of Shares without the written consent of such Underwriter. If, on the Closing Date or the Option Closing Date, as the case may be, any Underwriter or Underwriters shall fail or refuse to purchase Shares and the aggregate number of Shares with respect to which such default occurs is more than one-tenth of the aggregate number of Shares to be purchased on such date, and arrangements satisfactory to you and the Company for the purchase of such Shares are not made within thirty-six (36) hours after such default, this Agreement shall terminate without liability on the part of any non-defaulting Underwriter or the Company. In any such case, either you or the Company shall have the right to postpone the Closing Date or the Option Closing Date, as the case may be, but in no event for longer than seven days, in order that the required changes, if any, in the Registration Statement and in the Prospectus or in any other documents or arrangements may be effected. Any action taken under this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement. -17- 19 If this Agreement shall be terminated by the Underwriters, or any of them, because of any failure or refusal on the part of the Company to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform its obligations under this Agreement, the Company will reimburse the Underwriters or such Underwriters as have so terminated this Agreement with respect to themselves, severally, for all expenses (including the fees and disbursements of their counsel) reasonably incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder. This Agreement may be signed in two or more counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. -18- 20 This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York. Very truly yours, SILICON VALLEY GROUP, INC. By __________________________________________ Title _______________________________________ Accepted, October __, 1995 Morgan Stanley & Co. Incorporated Prudential Securities Incorporated Cowen & Company By Morgan Stanley & Co. Incorporated By _______________________________________ Morgan Stanley & Co. International Limited Prudential-Bache Securities (UK) Inc. Cowen & Company By Morgan Stanley & Co. International Limited By _______________________________________ -19- 21 SCHEDULE I U.S. Underwriters
Number of U.S. Firm Shares Underwriter To Be Purchased ----------- ---------------- Morgan Stanley & Co. Incorporated Prudential Securities Incorporated Cowen & Company ............................................ --------- Total U.S. Firm Shares ..................................... 2,800,000 =========
22 SCHEDULE II International Underwriters
Number of International Shares Underwriter To Be Purchased ----------- -------------------- Morgan Stanley & Co. International Limited Prudential-Bache Securities (UK) Inc. ......................... Cowen & Company ............................................... ------- Total International Shares .................................... 700,000 =======
23 SCHEDULE III Copies of paragraphs 5-10 of Article III of the Agreement Between U.S. and International Underwriters Each U.S. Underwriter represents that it has not offered or sold, and agrees not offer or sell, any Shares, directly or indirectly, in any province or territory of Canada in contravention of the securities laws thereof and, without limiting the generality of the foregoing, represents that any offer of Shares in Canada will be made only pursuant to an exemption from the requirement to file a prospectus in the province or territory of Canada in which such offer is made. Each U.S. Underwriter further agrees to send to any dealer who purchases from it any of the Shares a notice stating in substance that, by purchasing such Shares, such dealer represents and agrees that it has not offered or sold, and will not offer or sell, directly or indirectly, any of such Shares in any province or territory of Canada or to, or for the benefit of, any resident of any province or territory of Canada in contravention of the securities laws thereof and that any offer of Shares in Canada will be made only pursuant to an exemption from the requirement to file a prospectus in the province or territory of Canada in which such offer is made, and that such dealer will deliver to any other dealer to whom it sells any of such Shares a notice containing substantially the same statement as is contained in this sentence. The Underwriters understand that no action has been or will be taken in any jurisdiction by the Underwriters or the Company that would permit a public offering of the Shares, or possession or distribution of the Prospectus (as defined in the Underwriting Agreement), in preliminary or final form, in any jurisdiction where, or in any circumstances in which, action for that purpose is required, other than the United States. Each International Underwriter agrees that it will comply with all applicable laws and regulations, and make or obtain all necessary filings, consents or approvals, in each jurisdiction in which it purchases, offers, sells or delivers Shares (including, without limitation, any applicable requirements relating to the delivery of the international prospectus, in preliminary or final form), in each case at its own expense. In connection with sales of and offers to sell Shares made by it, such International Underwriter will either furnish to each person to whom any such sale or offer is made a copy of the then current international prospectus (in preliminary or final form and as then amended or supplemented if the Company shall have furnished any amendments or supplements thereto), or inform such person that such international prospectus, in preliminary or final form, will be made available upon request. Each International Underwriter further represents that it has not offered or sold, and agrees not to offer or sell, directly or indirectly, in Japan or to or for the account of any resident thereof, any of the Shares acquired in connection with the distribution contemplated hereby, except for offers or sales to Japanese International Underwriters or dealers and except 24 pursuant to any exemption from the registration requirements of the Securities and Exchange Law of Japan. Each International Underwriter further agrees to send to any dealer who purchases from it any of the Shares a notice stating in substance that, by purchasing such Shares, such dealer represents and agrees that it has not offered or sold, and will not offer or sell, any of such Shares, directly or indirectly, in Japan or to or for the account of any resident thereof except pursuant to any exemption from the registration requirements of the Securities and Exchange Law of Japan, and that such dealer will send to any other dealer to whom it sells any of such Shares a notice containing substantially the same statement as is contained in this sentence. Each International Underwriter further represents and agrees that (i) it has not offered or sold and will not offer or sell any Shares to persons in the United Kingdom except to persons whose ordinary activities involve them in acquiring, holding, managing or disposing of investments (as principal or agent) for the purposes of their businesses or otherwise in circumstances which have not resulted and will not result in an offer to the public in the United Kingdom within the meaning of the Public Offers of Securities Regulations 1995 (the "Regulations"); (ii) it has complied and will comply with all applicable provisions of the Financial Services Act 1986 and the Regulations with respect to anything done by it in relation to the Shares in, from or otherwise involving the United Kingdom; and (iii) it has only issued or passed on and will only issue or pass on to any person in the United Kingdom any document received by it in connection with the issue of the Shares, if that person is of a kind described in Article 11(3) of the Financial Services Act 1986 (Investment Advertisements) (Exemptions) Order 1995, or is a person to whom such document may otherwise lawfully be issued or passed on. Each International Underwriter agrees to indemnify and hold harmless each Underwriter and each person controlling any Underwriter from and against any and all losses, claims, damages and liabilities (including fees and disbursements of counsel) arising from any breach by it of any of the provisions of paragraphs seven, eight and nine of this Article III. EX-5.1 3 OPINION OF WILSON SONSINI GOODRICH & ROSATI, P.C. 1 EXHIBIT 5.1 [WSG&R LETTERHEAD] September 8, 1995 Silicon Valley Group, Inc. 2240 Ringwood Avenue San Jose, CA 95131 Re: Registration Statement on Form S-3 Ladies and Gentlemen: We have examined the Registration Statement on Form S-3 to be filed by you with the Securities and Exchange Commission on September 8, 1995, (the "Registration Statement") in connection with the registration under the Securities Act of 1933, as amended, of 4,025,000 shares of your Common Stock (the "Shares"). The Shares include an over-allotment option granted to the Underwriters to purchase 525,000 shares and are to be sold to the Underwriters as described in the Registration Statement for resale to the public. As your counsel in connection with this transaction, we have examined the proceedings taken and are familiar with the proceedings proposed to be taken by you in connection with the sale and issuance of the Shares. It is our opinion that upon conclusion of the proceedings being taken or contemplated by us, as your counsel, to be taken prior to the issuance of the Shares, and upon completion of the proceedings being taken in order to permit such transactions to be carried out in accordance with the securities laws of the various states where required, the Shares, when issued and sold in the manner described in the Registration Statement, will be legally and validly issued, fully paid and nonassessable. We consent to the use of this opinion as an exhibit to the Registration Statement, and further consent to the use of our name wherever appearing in the Registration Statement, including the prospectus constituting a part hereof, and any amendment thereto. Very truly yours, WILSON SONSINI GOODRICH & ROSATI Professional Corporation